compositions comprising cyclic purine dinucleotides with stereochemistry

专利摘要:
COMPOSITIONS UNDERSTANDING CYCLIC PURINE DYNUCLEOTIDES WITH STEREOCHEMICALS It is an object of the present invention to provide highly active and novel cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a newly discovered cytoplasmic receptor, known as STING (Interferon Gene Stimulator) . In particular, CDNs of the present invention are provided in the form of a composition that includes one or more cyclic purine dinucleotides that induce STING-dependent TBK1 activation, in which the cyclic purine dinucleotides present in the composition are Rp, Rp or stereoisomers Substantially pure Rp, Sp and particularly substantially pure Rp, Rp or RpSp CDN thiophosphate diastereoisomers.
公开号:BR112015013440B1
申请号:R112015013440-8
申请日:2013-12-13
公开日:2020-12-08
发明作者:Thomas W. Dubensky Jr.；David B. Kanne；Meredith Lai Ling Leong；Edward Emile Lemmens；Laura Hix Glickma
申请人:Aduro Biotech, Inc；
IPC主号:

专利说明:

[1] This application claims priority to provisional US Patent Application 61 / 737,006, filed on December 13, 2012, and to provisional US Patent Application 61 / 790,514, filed on March 15, 2013, which are hereby incorporated in their entirety, including all tables, figures, and claims. BACKGROUND OF THE INVENTION
[2] The following discussion of the fundamentals of the invention is provided only to assist the reader in understanding the invention and is not permitted to describe or constitute the state of the art of the present invention.
[3] The human immune system in general can be divided into two branches, known as "innate immunity" and "adaptive immunity". The innate branch of the immune system is predominantly responsible for the initial inflammatory reaction through a series of soluble factors, including the complement system and the chemokine / cytokine system; and a number of specialized cell types, including mast cells, macrophages, dendritic cells (DCs) and natural killer cells. In contrast, the adaptive immune branch involves a delayed and longer-lasting antibody response along with CD8 + and CD4 + T cell responses that play a critical role in immune memory against an antigen. A third branch of the immune system can be identified as involving Y T cells and T cells with limited T cell receptor repertoires, such as MAIT cells and NKT cells.
[4] For an effective immune response to an antigen, cells presenting antigens (APCs) must process and display the antigen in an appropriate MHC context for a T cell, which will then result in any stimulation of collaborating T cells (helper T lymphocytes) ) and cytotoxic. After antigen presentation, successful interaction of co-stimulatory molecules in both APCs and T cells must occur or activation will be aborted. GM-CSF and IL-12 serve as effective pro-inflammatory molecules in many tumor models. For example, GM-CSF induces myeloid precursor cells to proliferate and differentiate into dendritic cells (DCs) although additional signals are needed to activate their maturation for effective antigen-presenting cells necessary for the activation of T cells. Barriers to immune therapies effective include tolerance to the target antigen that can limit the induction of cytotoxic CD8 T cells of appropriate magnitude and function, poor trafficking of the generated T cells to malignant cell sites, and poor persistence of the T cell-induced response.
[5] DCs that phagocytize the remains of tumor cells process the material for the presentation of a major histocompatibility complex (MHC) that positively regulate the expression of costimulation molecules and migrate to regional lymph nodes that stimulate tumor-specific lymphocytes. This pathway results in the proliferation and activation of CD4 + and CD8 + T cells that react to tumor-associated antigens. In fact, such cells can be frequently detected in the blood, lymphoid tissues and malignant lesions of patients.
[6] New insights into the mechanisms underlying immune-avoidance, together with combination treatment regimens that enhance therapeutic vaccination activity - directly or indirectly - through combination with immune checkpoint inhibitors or other therapies, served as a basis for the development of vaccines that induce effective anti-tumor immunity. The cyclic-di-AMP (produced by Listeria monocytogenes) and its cyclic-di-GMP analog (produced by Legionella pneumophila) of the CDNs are recognized by the host cell as a PAMP (Pathogen Associated Molecular Pattern), which binds to the PRR ( Pathogen Recognition Receiver) known as STING. STING is an adapter protein in the cytoplasm of mammalian host cells that activates the TANK-binding kinase (TBK1) —IRF3 signaling axis, resulting in the induction of IFN-0 and other IRF-3 dependent gene products that activate strongly innate immunity. It is now recognized that STING is a component of the host's cytosolic surveillance pathway, which detects infection with intracellular pathogens and in response induces IFN-0 production, leading to the development of a pathogen specific adaptive protective immune response consisting of antigen-specific CD4 and CD8 T cells as well as pathogen specific antibodies. Examples of cyclic purine dinucleotides are described in detail in, for example, U.S. Patent Nos. 7,709,458 and 7,592,326; W02007 / 054279; and Yan et al., Bioorg. Med. Chem Lett. 18: 5631 (2008), each of which is incorporated herein by reference.
[7] There is still a need to improve compositions and methods for immunological strategies for treating diseases, such as cancer, that may be refractory to traditional therapeutic approaches. SUMMARY OF THE INVENTION
[8] It is an object of the present invention to provide highly active and novel cyclic-di-nucleotide (CDN) immune stimulators that activate DCs through a newly discovered cytoplasmic receptor, known as STING (Interferon Gene Stimulator). In particular, CDNs of the present invention are provided in the form of a composition that includes one or more cyclic purine dinucleotides that induce the activation of TBK1 STING-dependent, in which the cyclic purine dinucleotides present in the composition are Rp, Rp or stereoisomers Substantially pure Rp, Sp and diastereoisomers of Rp, Rp or RpSp CDN particularly substantially pure thiophosphate.
[9] In a first aspect, the present invention provides a composition that includes one or more cyclic purine dinucleotides, wherein the cyclic purine dinucleotides present in the composition are substantially pure Rp, Rp or Rp, Sp diastereoisomers, or prodrugs or respective pharmaceutically acceptable salts. These compositions, which induce the activation of TBK1 STING-dependent, may include one or more pharmaceutically acceptable excipients and may find use as adjuvants, as described in this document. Particularly preferred are cyclic purine dinucleotide thiophosphate derivatives as described below
[10] In their role as adjuvants, in certain embodiments the present compositions can be used as adjuvants in a therapeutic or prophylactic strategy that employs vaccine (s). Thus, substantially pure Rp, Rp or Rp, Sp diastereoisomers, or respective pharmaceutically acceptable prodrugs or salts, can be used in conjunction with one or more selected vaccines to stimulate an immune response to one or more predetermined antigens. The substantially pure Rp, Rp or Rp, Sp diastereoisomers, or respective prodrugs or pharmaceutically acceptable salts of the present invention can be supplied with or in addition to these vaccines.
[11] Such vaccine (s) may comprise inactivated or attenuated bacteria or viruses that comprise the antigens of interest, purified antigens, recombinantly delivered live viral or bacterial vectors designed to express and / or secrete the antigens, antigen presenting cell vectors (APC) comprising cells that are loaded with the antigens or transfected with a composition comprising a nucleic acid encoding the antigens, liposomal antigen delivery vehicles, or naked nucleic acid vectors encoding the antigens. This list is not intended to be a limiting factor. For example, such vaccines (s) may also include an inactivated tumor cell that expresses and secretes one or more of the GM-CSF, CCL20, CCL3, IL - 12 p 70, FLT-3 ligands.
[12] The compositions of the present invention can be administered to individuals in need of a variety of parenteral and non-parenteral routes in formulations containing pharmaceutically acceptable vehicles, adjuvants and carriers. Preferred routes are parenteral and include but are not limited to one or more of intradermal, intramuscular, intramuscular, intraarterial, subcutaneous, intrathecal, and epidural administrations. Particularly preferred is subcutaneous administration. Preferred pharmaceutical compositions are formulated as aqueous or oil-in-water emulsions.
[13] The pharmaceutical compositions of the present invention may comprise being administered alone or in combination with one or more additional pharmaceutically active components as adjuvants, lipids such as digitonin, liposomes, and CTLA-4 and PD-1 pathway antagonists, blocking agents via PD-1, inactivated bacteria that induce innate immunity (for example, inactivated or attenuated Listeria monocytogenes), compositions that mediate innate immune activation through Toll-type receptors (TLRs), type (NOD) receptors (NLRs) , receptors (RIG) -I based on inducible porretinoic acid genes (RLRs), type C lectin receptors (CLRs), pathogen-associated molecular patterns ("PAMPs"), chemotherapeutic agents, etc.
[14] As described below, cyclic purine dinucleotides formulated with one or more lipids may exhibit enhanced properties, including improved dendritic cell activation activity. Thus, the present invention also relates to a composition that comprises one or more CDNs and one or more lipids. In certain preferred embodiments, one or more CDNs are formulated with digitonin, a liposomal formulation and / or an oil-in-water emulsion. A composition according to one of claims 1-5, further comprising one or more of a CTLA-4 antagonist and a TLR-4 agonist.
[15] In preferred embodiments, one or more cyclic purine dinucleotides of thiophosphate comprise a thiophosphate diastereoisomer Rp, Rp or Rp, substantially pure Sp selected from the group consisting of c-di-AMP thiosphosphate, c-di-thiophosphate GMP, c-di-IMP thiophosphate, c-AMP-GMP thiophosphate, c-AMP-IMP thiophosphate and c-GMP-IMP thiophosphate or combinations thereof, including prodrugs and their pharmaceutically acceptable salts.
[16] In a related aspect, the present invention relates to methods of inducing, stimulating, or adjuvanting an immune response in an individual. These methods comprise administering to the individual a composition that includes one or more cyclic purine dinucleotides, wherein the cyclic purine thiophosphate dinucleotides present in the composition are substantially pure Rp, Rp or Rp, Sp diastereoisomers, or pharmaceutically acceptable prodrugs or salts. related. The preferred routes of administration are parenteral. As noted above, particularly preferred are the thiophosphate derivatives of such cyclic purine dinucleotides.
[17] In certain modalities, the method is a method of treating cancer. For example, the substantially pure Rp, Rp or Rp, Sp diastereoisomers, or respective pharmaceutically acceptable prodrugs or salts of the present invention can be provided together with, or in addition to, one or more cancer vaccine compositions that are known in the art. technical. The patient receiving such treatment may be suffering from cancer selected from the group consisting of a colorectal cancer cell, aero-digestive squamous cancer, lung cancer, brain cancer, liver cancer, stomach cancer, a sarcoma, leukemia, lymphoma, multiple myeloma, ovarian cancer, uterine cancer, breast cancer, melanoma, prostate cancer, pancreatic carcinoma and renal carcinoma. In other embodiments, the method is a method of inducing, stimulating, or adjuvanting an immune response to a pathogen.
[18] In yet other related aspects, the present invention relates to methods of inducing activation of STK-dependent TBK1 in an individual, which comprises administering one or more cyclic purine dinucleotides that link STING to the individual, in which the purine dinucleotides cyclics present in the composition are substantially pure Rp, Rp or Rp, Sp diastereoisomers, or respective prodrugs or pharmaceutically acceptable salts. The preferred routes of administration are parenteral. As noted above, particularly preferred are the thiophosphate derivatives of such cyclic purine dinucleotides.
[19] The methods described in this document may include administering to the mammal an effective amount of the substantially pure CDNs of the present invention, or prodrugs or pharmaceutically acceptable salts thereof, prior to or following primary therapy administered to the mammal to remove or kill cancer cells that express the cancer antigen. The compositions of the present invention can be provided as a neoadjuvant therapy; however, in preferred embodiments, the compositions of the present invention are administered after primary therapy. In various modalities, primary therapy comprises surgery to remove cancer cells from the mammal, radiation therapy to kill cancer cells in the mammal, or both surgery and radiotherapy.
[20] In other embodiments, the methods described in this document may include administering to the mammal an effective amount of the substantially pure CDNs of the present invention for the treatment of disorders in which changing immunity from Th1 to Th2 confers clinical benefit. Cell-mediated immunity (CMI) is associated with CD4 + TH1 T lymphocytes producing IL-2 cytokines, interferon (IFN) -y and tumor necrosis factor (TNF) -a. In contrast, humoral immunity is associated with IL-4, IL-6 and IL-10 producing CD4 + TH2 T lymphocytes. Immune deflection for TH1 responses normally produces activation of T cell cytotoxic lymphocytes (CTL), natural killer cells (NK), macrophages and monocytes. Generally, Th1 responses are more effective against intracellular pathogens (viruses and bacteria that are within host cells) and tumors, while Th2 responses are more effective against extracellular bacteria, parasites including helminths and toxins. In addition, activation of innate immunity is expected to normalize the T helper immune system balance type 1 and 2 (Th1 / Th2) and suppress the overreaction of Th2 type responses that cause immunoglobulin-dependent E allergies ( lg) and allergic asthma.
[21] BRIEF DESCRIPTION OF THE FIGURES
[22] Fig. 1 shows a general structure of CDNs.
[23] Fig. 2 shows a structure of c-di-GMP (compounds 11A) and c-di-AMP (compound 10A).
[24] Fig. 3 shows a structure of Rp, Rp-c-di-GMP-thiophosphate (compound 11B) and Rp, Rp-c-di-AMP-thiophosphate (compound 10B).
[25] Fig. 4 shows a structure of Rp, Sp-c-di-GMP-thiophosphate (compound 11C) and Rp, Sp-c-di-AMP-thiophosphate (compound 10C).
[26] Fig. 5 illustrates a structure of Sp, Sp-c-di-GMP-thiophosphate and Sp, Sp-c-di-AMP-thiophosphate.
[27] Fig. 6 shows a scheme of synthesis of AMP-di-c and c-di-AMP-thiophosphate.
[28] Fig. 7 depicts the induction of IFN- | 3 in antigen presenting cells by source CDNs and diastereoisomers of the corresponding dithio derived molecules.
[29] Fig. 8 shows the induction of IFN-p in antigen presenting cells by CDN diastereoisomers after treatment with snake venom phosphodiesterase
[30] Fig. 9 depicts O4-specific CD4 and CD8 T cell responses measured in PBMC at 10 days post vaccination in conjunction with CDN treatment.
[31] Fig. 10 shows CD4 and CD8 SIV gag-specific T cell responses measured in PBMC post-vaccination in conjunction with CDN treatment.
[32] Fig. 11 depicts the protection induced by CDN in a murine model of Listeria-OVA challenge.
[33] Fig. 12 shows antitumor efficacy induced by CDNs formulated with GVAX in a murine model of prostate cancer.
[34] Fig. 13 depicts the 2'-O-substituent analogs of CDNs of the present invention.
[35] Fig. 14 shows the synthesis of O- or S-prodrug analogs of CDNs of the present invention.
[36] Fig. 15 shows the induction of IFN-p in a human monocytic cell line after administration as a mono 2'-O-myristoyl c-di-GMP prodrug of c-di-GMP.
[37] Fig. 16 shows OVA-specific CD8 T cell responses after vaccination with a c-di-GMP mono-2'-0-myristoyl prodrug form of c-di-GMP. Detailed Description of the Invention
[38] The present invention relates to the use of highly active and new cyclic-di-nucleotide (CDN) immune stimulators that activate DCs through a newly discovered cytoplasmic receptor, known as STING (Interferon Gene Stimulator). In particular, CDNs of the present invention are provided in the form of a composition that includes one or more cyclic purine dinucleotides that induce the activation of TBK1 STING-dependent, in which the cyclic purine dinucleotides present in the composition are Rp, Rp or stereoisomers Substantially pure Rp, Sp and diastereoisomers of Rp, Rp or RpSp CDN particularly substantially pure thiophosphate.
[39] Recent insights into adjuvant design and development are informed by a fundamental understanding that conserved microbial structures known as Pathogen-Associated Molecular Patterns (PAMPs) are detected by the host cell's Standard Recognition Receptors (PRRs), triggering a cascade of downstream signaling resulting in the induction of cytokines and chemokines and the initiation of a specific adaptive immune response. The way the innate immune system is linked to a microbe's PAMP complement shapes the development of an appropriate adaptive response to prevent the invading pathogen from causing the disease. An objective of the adjuvant project is to select defined PAMPs or synthetic molecules specific for PRRs designated to initiate the desired response. Adjuvants such as monophosphoryl lipid A (MPL) and CpG are PAMPs recognized by Toll-like receptors (TLRs), a class of transmembrane PRRs that signal through MyD88 and Trif adapter molecules and mediate the induction of NF- -dependent pro inflammatory cytokines kB. MPL (TLR-4 agonist) and CpG (TLR-9 agonist) are clinically advanced adjuvants and are components of vaccines that are approved or pending FDA approval. Although TLRs present on the surface of cells (for example, TLR-4) and we endorse (for example, CpG) detect extracellular and vacuolar pathogens, the productive growth cycle of various pathogens, including viruses and intracellular bacteria, occurs in the cytosol. The compartmentalization of extracellular, vacuolar and cytosolic PRRs led to the hypothesis that the innate immune system distinguishes between pathogenic and non-pathogenic microbes through cytosol monitoring. It should be evident to those skilled in the art that PRR-specific agonists comprising a cytosolic surveillance pathway that initiates the development of protective immunity against intracellular pathogens and is relevant to the vaccine. These same targeting ligands will also be essential in the development of effective vaccines targeting malignancies, known to require tumor-specific CD4 + and CD8 + T cells.
[40] Activation of the Cytosolic Surveillance Pathway (CSP) is integral to the development of protective immunity for intracellular pathogens. CSP detects bacterial, viral and protozoan pathogens, leading to activation of the TANK-binding kinase (TBK-1) / IRF-3 signaling axis and induction of IFN-J3 and other co-regulated genes. Viral and bacterial nucleic acids both activate this pathway, and IFN-P induction is MyD88 and Trif- independent. Although type I interferon is often thought of primarily as an anti-viral host response, IFN-p induction is a hallmark of cytosolic growth in macrophages infected with the intracellular bacteria Listeria monocytogenes (Lm). A known dichotomy in the mouse model of listeriosis is that, while wild-type Lm prepares potent CD4 and CD8 T-cell immunity that protects mice against bacterial challenge, vaccination with listeriolysin Lm The LLO-excluded does not contain functional T cells or induces protective immunity. This difference is proof of the requirement for expression of host cell genes and cytosolic access by Lm to bring about functional protective immunity mediated by T-cell. The level of IFN-β in infected host cells is regulated by Lm multi-drug efflux pumps (MDRs), which secrete small structurally independent molecules, including antibiotics. IFN-p is not induced in host cells infected with LLO Lm mutants that are confined to the phagolysosome. Normal levels of IFN-p are induced in MyDÕK1 'Trif1' deficient macrophages deficient in all TLR-mediated signaling. These data demonstrate that, although Lm binds to TLRs, in response to wild-type Lm infection, host cell CSP is necessary for the development of protective immunity, correlated with IFN-p induction.
[41] The term "cyclic-di-nucleotides" ("CDNs") as used herein refers to a class of molecules comprising 2'-5 'or 3'-5' phosphodiester bonds between two purine nucleotides . This includes 2'-5'-2 ', 5', 2'-5'-3'5 'and S'.S'-S'.S' connections. CDNs activate the cytosolic surveillance pathway by directly linking two cytosolic PRRs, DDX41 and STING. Type I interferon response to infection by other intracellular bacteria and Lm results from the secretion of c-di-AMP or its related cyclic dinucleotide (CDN), c-di-GMP, and its direct binding to DDX41 and the DEAD helicase box. (aspartate-glutamate-alanine-aspartate) and STING (Interferon Gene Stimulator), a recently defined receptor of the cytosolic surveillance pathway. CDNs are second messengers expressed by most bacteria and regulate diverse processes, including motility and biofilm formation. CDNs bind with high affinity to DDX41 and the complex with the STING adapter protein, resulting in activation of the TBK1 / 1RF3 signaling pathway, and inducing IFN-p and other IRF-3 dependent gene products that strongly activate innate immunity .
[42] Native CDN molecules are sensitive to degradation by phosphodiesterases that are present in host cells, for example in antigen presenting cells, which occupy vaccine formulations that contain said native CDN molecules. The potency of a defined adjuvant can be diminished by this degradation, since the adjuvant would be unable to bind and activate its defined PRR target. Lower adjuvant potency could be measured, for example by a lesser amount of induced expression of a signature molecule of innate immunity (for example, IFN-J3), correlated with weaker vaccine potency, as defined by the magnitude of the immune response antigen-specific measure.
[43] In the present invention, c-di-AMP and GMP-di-c dithio diphosphate derivatives are provided. The process synthesis for said dithio diphosphate derivatives results from c-di-AMP and GMP-di-c molecules in a mixture of diastereoisomers, including Rp, Rp, Sp, Sp and Rp, Sp derived from dithio- diphosphate of c-di-AMP and GMP-di-c molecules. It has previously been shown that said mixtures of diastereoisomers containing Rp, Rp and Rp derivatives, c-di-GMP dithio diphosphate Sp recruited and activated inflammatory cells into the bronchoalveolar spaces when administered to rats intranasally. However, there was no evidence that these such c-di-GMP dithio diphosphate derivatives provided any advantages with regard to stimulating an immune response compared to the originating c-di-GMP molecules and in fact , these c-di-GMP dithio diphosphate preparations had only similar or weaker potency compared to the original c-di-GMP molecules.
[44] Definitions
[45] "Administration" as used herein with respect to a human, mammal, mammalian subject, animal, veterinary subject, placebo subject, research object, experimental subject, cell, tissue, organ or biological fluid, refers to if without limitation the contact of the exogenous ligand, reagent, placebo, small molecule, pharmaceutical agent, therapeutic agent, diagnostic agent or composition to the subject, cell, tissue, organ, or biological fluid and the like. "Administration" may refer, p. eg, therapy, pharmacokinetics, diagnosis, research, placebo and experimental methods. Treatment of a cell encompasses the contact of a reagent with the cell, as well as the contact of a reagent with a fluid, where the fluid is in contact with the cell. "Administration" also includes in vitro and ex vivo treatments, e.g. eg from a cell, by a reagent, diagnosis, binding composition, or by another cell. By "administered together" is not to imply that two or more agents are administered as a single composition. Although administration as a single composition is contemplated by the present invention, such agents can be delivered to a single subject as separate administrations, which can be at the same time or not, and which can be by the same route or different routes of administration.
[46] An "agonist", as it relates to a ligand and receptor, comprises a molecule, combination of molecules, a complex or combination of reagents, that stimulate the receptor. For example, a granulocyte-macrophage colony-stimulating factor agonist (GM-CSF) may encompass GM-CSF, a mutein or a derivative of GM-CSF, a GM-CSF mimetic peptide, an antibody that stimulates GM receptors -CSF or a small molecule that mimics the biological function of the GM-CSF receptor.
[47] An "antagonist", as it relates to a ligand and receptor, comprises a molecule, combination of molecules or complex, which inhibits, neutralizes, down-regulates, and / or desensitizes receptors. "Antagonist" encompasses any reagent that inhibits the constitutive activity of the receptor. A constitutive activity is one that manifests itself in the absence of a linker / receptor interaction. "Antagonist" also encompasses any reagent that inhibits or prevents stimulated (or regulated) activity at a receptor. For example, a GM-CSF receptor antagonist includes, without limitation, an antibody that binds the ligand (GM-CSF) and prevents it from binding to the receptor, or an antibody that binds to the receptor and prevents receptor binding ligand, or where the antibody blocks the receptor in an inactive conformation.
[48] As used herein, an "analog" or "derivative" with reference to a peptide, polypeptide or protein refers to another peptide, polypeptide or protein that has an identical or similar function as the original of the peptide, polypeptide or protein, but does not necessarily comprise a similar or identical amino acid sequence or structure of the original peptide, polypeptide, or protein. An analogue preferably satisfies at least one of the following: (a) a protein agent having an amino acid sequence that is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical the original amino acid sequence (b) a protein agent encoded by a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence encoding the original amino acid sequence; and (c) a protein agent encoded by a nucleotide sequence that is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to the nucleotide sequence encoding the amino acid sequence original.
[49] "Antigen presenting cells" (APCs) are immune system cells used for the presentation of T cell antigen. APCs include dendritic cells, monocytes, macrophages, marginal zone Kupffer cells, microglia, Langerhans cells, cells T and B cells. Dendritic cells occur in at least two strains. The first strain comprises pre-DC1, myeloid DC1 and mature DC1. The second strain comprises potent CD34 + CD45RA'multi-starting progenitor cells, CD34 + CD45RA + cells, CD34 + CD45RA + CD4 + IL-3Ra + pro-DC2 cells, pre-DC2 plasmacytoid CD4 + CD11c cells, lymphoid DC2-derived plasmocytoid DC2s human and mature DC2s.
[50] "Attenuation" and "attenuated" encompasses a bacterium, virus, parasite, infectious organism, prion, tumor cell, gene in the infectious organism and the like, which is modified to reduce toxicity to a host. The host can be a human or animal host, or an organ, tissue, or cells. The bacterium, to give an example without limitation, can be attenuated to reduce binding to a host cell, to reduce the spread from one host cell to another host cell, to reduce extracellular growth, or to reduce intracellular growth in a cell hostess. Attenuation can be assessed by measuring, for example, toxicity indexes or indications, the LD50, the organ clearance rate, or the competitive index (see, for example, Auerbuch, et al. (2001) Infect. Immunity 69 : 5953-5957). Generally, an attenuation results in an increase in LD50 and / or an increase in the clearance rate of at least 25%; more generally at least 50%; more generally, at least 100% (2-fold); usually at least 5-times; more usually at least 10-times; more usually at least 50-times; often at least 100-times; more times at least 500-times; and, more often at least 1000-times; usually at least 5000-times; more generally at least 10,000-times; and more usually at least 50,000-times; and most of the time at least 100,000-times.
[51] By "purified" and "isolated" is meant that a specified species is responsible for at least 50%, more often it is responsible for at least 60%, typically it is responsible for at least 70%, more typically it is responsible by at least 75%, more typically it is responsible for at least 80%, it is usually responsible for at least 85%, more usually it is responsible for at least 90%, more usually it is responsible for at least 95%, and conventionally it is responsible for at least 98% by weight, or more, of the species present in a composition. Weights of water, buffers, salts, detergents, reducers, protease inhibitors, stabilizers (including an added protein such as albumin) and excipients are generally not used in determining purity.
[52] "Specifically" or "selectively" binds, when referring to a ligand / receptor, complementary nucleic acid / nucleic acid, antibody / antigen or other binding pair (for example, a cytokine to a cytokine receptor) (each commonly referred to as a "target" biomolecule or a "target") indicates a binding reaction, which is related to the presence of the target in a heterogeneous population of proteins and other biological products. Specific binding may mean, for example, that the binding compound, nucleic acid ligand, antibody or binding composition derived from the antigen binding site of an antibody of the contemplated method binds to its target with an affinity that is often bigger, at least 25% more often at least 50% bigger, more often at least 100% (2-times) bigger, usually at least ten times bigger, more usually at least 20 times bigger and more usually at least 100 times bigger than affinity with a non-target molecule.
[53] "Ligand" refers to a small molecule, nucleic acid, peptide, polypeptide, saccharide, polysaccharide, glycan, glycoprotein, glycolipid, or combinations thereof, that bind to a target biomolecule. Although such ligands can be agonists or antagonists of a receptor, a ligand also includes a binding agent that is not an agonist or antagonist and has no agonist or antagonist properties. A ligand's specific binding to its cognate target is often expressed in terms of an "affinity". In preferred embodiments, the Binders of the present invention bind with affinities of between about O4 M'1 and about 108 M'1. Affinity is calculated as Kd = koff / kon (koff is the dissociation rate constant, Kon is the association rate constant and Kd is the equilibrium constant).
[54] Affinity can be determined at steady state by measuring the bound fraction (r) of labeled ligand in various concentrations (c). The data are plotted using the Scatchard equation: r / c = K (n-r): where r = moles of bound ligand / mol of the receiver at steady state; c = concentration of the free ligand at steady state; K = equilibrium association constant; and n = number of ligand binding sites per receptor molecule. By graphical analysis, r / c on the y axis versus r on the x axis is plotted, thus producing a Scatchard plot. Affinity measurement by Scatchard analysis is well known in the art. See, for example, van Erp et al., J. Immunoassay12: 425-43, 1991; Nelson and Griswold, Comput. Biomed Methods Programs. 27: 65-8, 1988. Alternatively, affinity can be measured by isothermal titration calorimetry (ITC). In a typical ITC experiment, a ligand solution is titrated to a solution of its target cognate. The heat released through its interaction (AH) is monitored over time. As successive amounts of the binder are titrated in the ITC cell, the amount of heat absorbed or released is in direct proportion to the amount of binding. As the system reaches saturation, the heat signal decreases until only dilution heats are observed. A binding curve is then obtained from a graphical representation of the heat of each injection against the ratio between ligand and binding partner in the cell. The binding curve is analyzed with the appropriate binding model to determine AH, n and KB. Note that KB = 1 / Kd-
[55] The term "subject" as used in this document refers to a human or non-human organism. Accordingly, the methods and compositions described in this document are applicable to human and veterinary diseases. In certain modalities, subjects are "patients", that is, living human beings who are receiving medical care for a disease or condition. This includes people with no definite illness who are being investigated for signs of pathology. Preferred are subjects who have an existing diagnosis of a specific cancer that is being targeted by compositions and methods of the present invention. Preferred cancers for treatment with the compositions described herein include but are not limited to prostate cancer, renal carcinoma, melanoma, pancreatic cancer, cervical cancer, ovarian cancer, colon cancer, head & neck cancer, lung cancer and breast cancer.
[56] "Therapeutically effective amount" is defined as an amount of a reagent or pharmaceutical composition that is sufficient to show a patient benefit, that is, to cause a decrease, prevention or improvement in the symptoms of the condition being treated. When the pharmaceutical agent or composition comprises a diagnostic agent, an "effective diagnostic amount" is defined as an amount that is sufficient to produce a signal, image or other diagnostic parameter. Effective amounts of the pharmaceutical formulation will vary according to factors such as the individual's degree of susceptibility, the individual's age, sex and weight and the individual's idiosyncratic responses. "Effective amount" includes, without limitation, an amount that can alleviate, reverse, mitigate, prevent or diagnose a symptom or sign of a medical condition or disease or a related causal process. Unless otherwise stated, explicitly or contextually, an "effective amount" is not limited to a minimum amount sufficient to alleviate a condition.
[57] "Treatment" or "treating" (in relation to a condition or disease) is an approach to obtaining beneficial or desired results including and preferably clinical results. For the purposes of the present invention, beneficial or desired results in relation to a disease include, but are not limited to, one or more of the following: preventing a disease, improving a condition associated with a disease, curing diseases, decreasing the severity of an illness, delay the progression of an illness, relieve one or more symptoms associated with an illness, increase the quality of life of someone suffering from an illness, and / or prolong survival. Likewise, for the purposes of the present invention, beneficial or desired results with respect to a condition include but are not limited to one or more of the following: preventing a condition, improving a condition, curing a disease, decreasing the severity of a condition disease, delaying the progression of a disease, relieving one or more symptoms associated with a condition, increasing the quality of life of someone suffering from a condition, and / or prolonging survival. For example, in embodiments where the compositions described herein are used for the treatment of cancer, beneficial or desired results include, but are not limited to, one or more of the following options: reduce the proliferation of (or destroy) neoplastic or cancer cells, reduce the metastasis of neoplastic cells found in cancers, reduce the size of the tumor, decrease the symptoms resulting from cancer, increase the quality of life of those suffering from cancer, decrease the dose of other drugs needed to treat the disease, delay the progression of the cancer , and / or prolong the survival of cancer patients. Depending on the context, a subject's "treatment" may imply that the subject is in need of treatment, for example, in the situation where the subject understands a disorder that is expected to be alleviated by the administration of a reagent.
[58] By "purified" and "isolated" is meant, when referring to a polypeptide, that the polypeptide is present in the substantial absence of the other biological macromolecules with which it is associated in nature. The term "purified" as used in this document means that an identified polypeptide is responsible for at least 50%, more often it is responsible for at least 60%, typically it is responsible for at least 70%, more typically it is responsible for at least 75% , more typically it is responsible for at least 80%, it is usually responsible for at least 85%, more usually it is responsible for at least 90%, more usually it is responsible for at least 95%, and conventionally it is responsible for at least 98% in weight or more of the polypeptides present. Weights of water, buffers, salts, detergents, reducers, protease inhibitors, stabilizers (including a protein added such as albumin) and excipients and molecules with a molecular weight of less than 1000 are generally not used in determining the polypeptide purity. See, for example, Pat's discussion of purity. No. 6,090,611, issued to Covacci, et al.
[59] "Peptide" refers to a small sequence of amino acids, where the amino acids are linked together by peptide bonds. A peptide can occur free or linked to another fraction, such as a macromolecule, lipids, oligo or polysaccharide, or a polypeptide. Where a peptide is incorporated into a polypeptide chain, the term "peptide" can still be used to refer specifically to the small sequence of amino acids. A "peptide" can be connected to another fraction via a peptide bond or some other type of bond. A peptide is at least two amino acids in length and generally less than about 25 amino acids in length, where maximum length is a custom function or context. The terms "peptide" and "oligopeptides" can be used interchangeably.
[60] "Protein" generally refers to the sequence of amino acids comprising a polypeptide chain. Protein can refer to a three-dimensional structure of the polypeptide. "Denatured protein" refers to a partially denatured polypeptide, having a residual three-dimensional structure or, alternatively, an essentially random, i.e., fully denatured, three-dimensional structure. The invention encompasses reagents and methods using polypeptide variants, for example, involving glycosylation, phosphorylation, sulfation, disulfide bond formation, deamidation, isomerization, cleavage points in signal or leader sequence processing, covalent bonds and bound cofactors and not covalently bound, oxidized variants and the like. The formation of bound disulfide proteins is described (See, for example, Woycechowsky and Raines (2000) Curr. Opin. Chem. Biol. 4: 533539; Creighton, et al. (1995) Trends Biotechnol. 13: 18-23) .
[61] "Recombinant" when used with reference, for example, to a nucleic acid, cell, animal, virus, plasmid, vector or the like, indicates modification by the introduction of an exogenous, non-native nucleic acid, alteration of an acid native nucleic acid, or by derivation, in whole or in part, of a recombinant nucleic acid, cell, virus, plasmid or vector. Recombinant protein refers to a protein derived, for example, from a recombinant nucleic acid, virus, plasmid, vector or the like. "Recombinant bacteria" includes bacteria where the genome is designed by recombinant methods, for example, by means of a mutation, deletion, insertion and / or rearrangement. "Recombinant bacteria" also encompasses a bacterium modified to include extra-genomic recombinant nucleic acids, for example, a plasmid or a second chromosome or bacteria where an existing extra-genomic nucleic acid is altered.
[62] "Sample" refers to a sample from a human, animal, placebo or research sample, for example, a cell, tissue, organ, liquid, gas, aerosol, slurry, colloid, or coagulated material. The "sample" can be tested in vivo, for example, without removing human or animal, or it can be tested in vitro. The sample can be tested after processing, for example, by histological methods. "Sample" also refers, for example, to a cell that comprises a fluid or tissue sample or cell separate from a fluid or tissue sample. "Sample" can also refer to a cell, tissue, organ, or fluid that has just been taken from a human or animal, or a cell, tissue, organ or liquid that is processed or stored.
[63] "Vaccine" includes preventive vaccines. Vaccine also encompasses therapeutic vaccines, for example, a vaccine administered to a mammal that comprises a condition or disorder associated with the antigen or epitope provided by the vaccine.
[64] The term "antibody" in this document refers to a peptide or polypeptide derived from, modeled after or substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, capable of binding specifically to an antigen or epitope . See, for example, Fundamental Immunology, 3rd Edition, W.E. Paul, ed., Raven Press, N.Y. (1993); Wilson (1994; J. Immunol. Methods 175: 267-273; Yarmush (1992) J. Biochem. Biophys. Methods 25: 85-97. The term antibody includes antigen-binding portions, that is, "antigen-binding sites antigen "(e.g. fragments, subsequences, complementarity determining regions (CDRs)) that retain the ability to bind to the antigen, including a monovalent fragment consisting of (i) a Fab fragment, a monovalent fragment consisting of VL, VH domains , CL and CHI; (ii) an F (ab ') 2 fragment, a divalent fragment, comprising two Fab fragments linked by a disulfide bridge in the hinge region; (iii) an Fd fragment consisting of the VH and CHI domains; ( iv) an Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341: 544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR). Single chain antibodies are also included by reference in the te "antibodies".
[65] Cyclic Purine Dinucleotides
[66] As described in this document, the present invention relates to sterically chemically purified cyclic purine dinucleotides that induce the activation of STK-dependent TBK1 and its methods of preparation and use.
[67] Prokaryotic cells, as well as eukaryotic cells use several small molecules for cell signaling and intra- and intercellular communication. Cyclic nucleotides such as cGMP, cAMP etc. they are known to have regulatory and initiatory activity in pro and eukaryotic cells. Unlike eukaryotic cells, prokaryotic cells also use cyclic purine dinucleotides as regulatory molecules. In prokaryotes, the condensation of two GTP molecules is catalyzed by the enzyme diguanylate cyclase (DGC) to yield c-diGMP, which represents an important regulator in bacteria.
[68] Recent work suggests that CDNs such as cyclic diGMP or respective analogues may also stimulate or increase the immune or inflammatory response in the patient or may improve the immune response to the vaccine, serving as an adjuvant in mammals. Cytosolic detection of pathogen-derived DNA requires signaling through TANK-binding kinase 1 (TBK1) and its downstream transcription factor, IFN-regulating factor 3 (IRF3). A transmembrane protein called STING (IFN gene stimulator; also known as MITA, ERIS, MPYS and TMEM173) functions as a signaling receptor for these cyclic purine dinucleotides, causing stimulation of the TBK1-IRF3 signaling axis and a STING-dependent response type I interferon. See, for example, Fig. 1. Burdette et al., Nature 478: 515-18, 2011 demonstrated that STING binds directly to cyclic diguanylate monophosphate, but not to other independent nucleotides or nucleic acids.
[69] The goal of vaccine formulation is typically to offer a combination of antigens and adjuvants capable of generating a sufficient population of T cells and / or memory B cells to react quickly to a pathogen, tumor cell, etc. having an antigen of interest. The present invention relates to methods for providing adjuvant compositions comprising one or more cyclic purine dinucleotides, in which the cyclic purine dinucleotides present in the composition are substantially pure diastereoisomers Rp, Rp or Rp, Sp, methods for their manufacture and methods for the respective use of stimulating an immune response in an animal.
[70] Preferred cyclic purine dinucleotides include but are not limited to c-di-AMP, GMP-di-c, c-di-IMP, c-AMP-GMP, c-AMP-IMP and c-GMP-IMP and respective analogs, including, but not limited to, phosphorothioate analogs, referred to as "thiophosphates". A general structure of the CDN thiophosphate is provided in Fig. 1. In this figure, B1 and B2 represent the base fraction. Phosphorothioates are a variant of normal nucleotides, in which one of the non-bridged oxygen is replaced by a sulfur. Sulphurization of the internucleotide bond dramatically reduces the action of endo- and exonucleases, including POL exonuclease from DNA 1 51 to 3 'and 31 to 5', S1 and P1 nucleases, RNases, serum nucleases and snake venom phosphodiesterase. In addition, it increases the potential to cross the lipid bilayer.
[71] A phosphorothioate bond is inherently chiral. One skilled in the art will recognize that the phosphates in this structure can each exist in forms of R or S. Thus, forms of Rp, Rp, Sp.Sp and Rp, Sp are possible. In each case, the substantially pure Rp, Rp and Rp, Sp diastereoisomers of these molecules are preferred. Examples of such CDN thiophosphate molecules are depicted in figs. 2-6, showing forms of Rp thiophosphate, Rp-c-di-adenosine monophosphate; RP, Sp-c-di-adenosine monophosphate; RP, Rp-c-di-guanosine monophosphate and Rp, Sp-c-di-guanosine monophosphate. In these figures, the stereochemistry of the phosphate center is shown as R or S, as the case may be.
[72] Preferred cyclic purine dinucleotides also include 2'-O-substituent forms of CDNs and in particular CDN thiophosphates. Additional bioavailability and stability can be provided by replacing 2'-OH of the ribose fraction. An example of such 2'-O-substituents analogs are shown in Fig. 11. Favorable substituent groups in this document include, without limitation, halogen, hydroxyl, alkyl, alkenyl, alkynyl, acyl (-C (0) Raa), carboxyl ( -C (0) 0-Raa), aliphatic groups, alicyclic groups, alkoxy, substituted oxy (-0-Raa), aryl, aralkyl, heterocyclic radical, heteroaryl, heteroarylalkyl, amino (-N (Rbb) (RCc))> imino (= NRbb), starch (-C (0) N (Rbb) (Rcc) or -N (Rbb) C (0) Raa), azido (-N3), nitro (-N02), cyan (- CN) , carbamido (-OC (0) N (Rbb) (Rcc) or -N (Rbb) C (0) ORaa), ureido (- N (Rbb) C (O) -N (Rbb) (Rcc)), thioureide (-N (Rbb) C (S) N (Rbb) (Rcc)), guanidinyl (- N (Rbb) C (= NRbb) N (Rbb) (Rcc)), amidinyl (-C (= NRbb) N ( Rbb) (Rcc) or - N (Rbb) C (-NRbb) (Raa)), thiol (-SRbb), sulfinyl (-S (0) Rbb), sulfonyl (-S (0) 2Rb) and sulfonamidyl (- S (0) 2N (Rbb) (Rcc) or -N (Rbb) S (0) 2Rbb). Where each Raa, Rbb and RcC are independently H, an optionally bonded functional chemical group or an additional substituent group with a preferred list, including without limitation H, alkyl, alkenyl, alkynyl, aliphatic, alkoxy, acyl, aryl, aralkyl , heteroaryl, alicyclic, heterocyclic and heteroarylalkyl. Substituents selected within the compounds described in this document are present recursively.
[73] Yet other preferred cyclic purine dinucleotides also include S-substituting forms of CDNs, and in particular CDN thiophosphates, which can advantageously provide pro-drugs with better bioavailability. The term "pro-drug" as used in this document refers to a modification of the contemplated compounds, in which the modified compound is converted within the body (for example, into a target cell or the target organ) back to unmodified form through enzymatic or non-enzymatic reactions. In certain embodiments, the hydroxyl in a ribose comprises a prodrug abandonment group. Pro-drugs can modify the physical-chemical, biopharmaceutical and pharmacokinetic properties of drugs. Traditional pro-drugs are classified as drugs that are activated through in vivo transformation to form the active drug. Reasons for the development of the prodrug are typically poor aqueous solubility, chemical instability, low oral bioavailability, lack of blood-brain barrier penetration and high first-pass metabolism associated with the parent drug. Suitable pro-drug fractions are described in, for example, “Prodrugs and Targeted Delivery,” J. Rautico, Ed., John Wiley & Sons, 2011.
[74] An example of such prodrug analogues is shown in Fig. 12. This form of prodrug with improved lipophilicity can be cleaved into active forms through the action of esterases present in target organisms. Favorable substituent groups in this document include, without limitation, halogen, hydroxyl, alkyl, alkenyl, alkynyl, acyl (-C (0) Raa), carboxyl (-C (0) 0-Raa), aliphatic groups, alicyclic groups, alkoxy, substituted oxy (-O-Raa), aryl, aralkyl, heterocyclic radical, heteroaryl, heteroarylalkyl, amino (-N (Rbb) (Rcc)), imino (= NRbb), starch <-C (0) N (Rbb) ( Rcc) or - N (Rbb) C (0) Raa), azido (-N3), nitro (-N02), cyan (-CN), carbamido (- OC (0) N (Rbb) (Rcc) or -N (Rbb) C (0) ORaa), ureide (-N (Rbb) C (O) -N (Rbb) (Rcc)), thioureide (-N (Rbb) C (S) N (Rbb) (Rcc)) , guanidinyl (-N (Rbb) C (= NRbb) N (Rbb) (Rcc)), amidinyl (-C (= NRbb) N (Rbb) (Rcc) or -N (Rbb) C (= NRbb) (Raa )), thiol (-SRbb), sulfinyl (-S (0) Rbb), sulfonyl (-S (0) 2Rb) and sulfonamidyl (-S (0) 2N (Rbb) (Rcc) or - N (Rbb) S (0) 2Rbb). Where each Raa, Rbb and RcC are independently H, an optionally bonded functional chemical group or an additional substituent group with a preferred list, including without limitation H, alkyl, alkenyl, alkynyl, aliphatic, alkoxy, acyl, aryl, aralkyl, heteroaryl, alicyclic, heterocyclic and heteroarylalkyl. Substituents selected within the compounds described in this document are present recursively. Preferred substituents include methyl, isopropyl and t-butyl. Nucleotide prodrug forms are known in the art. See, for example, Nucleotide Prodrugs for HCV Therapy, Sofia, M.J., Antiviral Chem and Chemother. 2011, 22: 23-49; Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA - Dependent RNA - Polymerase, Sofia, M.J., et al., J. Med. Chem., 2012, 55: 2481-2531.
[75] The term "alkyl", as used here, refers to a straight or branched saturated hydrocarbon radical that contains up to twenty-four carbon atoms. Examples of alkyl groups include without limitation methyl, ethyl, propyl, butyl, isopropyl, n-hexyl, octyl, decyl, dodecyl and the like. Alkyl groups typically include 1 to 24 carbon atoms, more typically 1 to 12 carbon atoms, with 1 to about 6 carbon atoms being more preferred. The term "low alkyl" as used herein includes from about 1 to about 6 carbon atoms. Alkyl groups as used herein can optionally include one or more substituent groups.
[76] The term "alkenyl" as used herein, alone or in combination, refers to a straight or branched chain hydrocarbon radical containing up to 24 carbon atoms and having at least one carbon-carbon double bond. Examples of alkenyl groups include without limitation ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, dienes such as 1,3-butadiene and the like. Alkenyl groups typically include from 2 to 24 carbon atoms, more typically from 2 to 12 carbon atoms, with 2 to about 6 carbon atoms being more preferred. Alkenyl groups as used herein can optionally include one or more substituent groups.
[77] The term "alkynyl" as used herein, alone or in combination, refers to a straight or branched chain hydrocarbon radical containing up to 24 carbon atoms and having at least one carbon-carbon triple bond. Examples of alkynyl groups include, without limitation, ethynyl, 1-propynyl, 1-butynyl and the like. Alkynyl groups typically include from 2 to 24 carbon atoms, more typically from 2 to 12 carbon atoms, with 2 to about 6 carbon atoms being more preferred. Alkynyl groups as used herein may optionally include one or more additional substituent groups.
[78] The term "acyl," as used here, refers to a radical formed by the removal of a hydroxyl group from an organic acid and has the general formula -C (O) -X where X is normally aliphatic, alicyclic or aromatic. Examples include aliphatic carbonyls, aromatic carbonyls, aliphatic sulfonis, aromatic sulfinis, aliphatic sulfinis, aromatic phosphates, aliphatic phosphates and the like. Acyl groups as used here can optionally include more substituent groups.
[79] The term "alicyclic" refers to a cyclic ring system, in which the ring is aliphatic. The ring system can comprise one or more rings, where at least one ring is aliphatic. Alicyclic preferences include rings having from about 5 to about 9 carbon atoms in the ring. Alicyclic as used here can optionally include more substituent groups.
[80] The term "aliphatic", as used here, refers to a straight or branched hydrocarbon radical containing up to twenty-four carbon atoms in which the saturation between any two carbon atoms is a single, double or triple bond . An aliphatic group preferably includes from 1 to 24 carbon atoms, more typically from 1 to 12 carbon atoms, with 1 to about 6 carbon atoms being more preferred. The straight or branched chain of an aliphatic group can be disrupted with one or more heteroatoms that include nitrogen, oxygen, sulfur and phosphorus. Such heteroatoms-disrupted aliphatic groups include, without limitation, polyalkoxides, such as polyalkylene glycols, polyamines and polyimines. Aliphatic groups as used here can optionally include more substituent groups.
[81] The term "alkoxy", as used here, refers to a radical formed between an alkyl group and an oxygen atom, in which the oxygen atom is used to join the alkoxy group to a parent molecule. Examples of alkoxy groups include, without limitation, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, neopentoxy, n-hexoxy and the like. Alkoxy groups as used herein can optionally include more substituent groups.
[82] The term "aminoalkyl" as used herein, refers to an amino-substituted C -Cn alkyl radical. The alkyl portion of the radical forms a covalent bond with a parent molecule. The amino group can be located at any position and the aminoalkyl group can be replaced with an additional substituent group on the alkyl and / or the amino parts.
[83] The terms "aralkyl" and "arylalkyl", as used herein, refer to an aromatic group that is covalently attached to a C -Cn alkyl radical. The alkyl radical part of the resulting aralkyl (or arylalkyl) group forms a covalent bond with a parent molecule. Examples include, without limitation, benzyl, phenethyl and the like. Aralkyl groups in this document may optionally include more substituent groups attached to alkyl, aryl or both groups that form the radical group.
[84] The terms "aryl" and "aromatic" in this document refer to mono- or polycyclic carbocyclic ring system radicals having one or more aromatic rings. Examples of aryl groups include, without limitation, phenyl, naphthyl, tetrahydronaphthyl, indanyl, idenyl and the like. Preferred aryl ring systems have from about 5 to about 20 carbon atoms in one or more rings. Aryl groups as used here can optionally include more substituent groups.
[85] The terms "halogen" or "halo", as used in this document, refer to an atom selected from fluorine, chlorine, bromine and iodine.
[86] The terms "heteroaryl" and "heteroaromatic" in this document refer to a radical comprising a mono- or polycyclic aromatic ring, ring system or fused ring system in which at least one of the rings is aromatic and includes one or more heteroatoms. Heteroaryl should also include fused ring systems including systems where one or more of the fused rings do not contain hetero atoms. Heteroaryl groups typically include a ring atom, selected from sulfur, nitrogen or oxygen. Examples of heteroaryl groups include, without limitation, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazole, thiazoyl, oxazool, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazoline, benzimidazoline, benzimidazoline, benzimidazoline Heteroaryl radicals can be attached to a parent molecule directly or through a bonding fraction such as an aliphatic group or hetero-atom. Heteroaryl groups as used herein can optionally include more substituent groups.
[87] The term "heteroarylalkyl", as used herein, refers to a group of heteroaryl as previously defined which further includes a covalently bonded alkyl radical CrC12. The alkyl radical part of the resulting heteroarylalkyl group is capable of forming a covalent bond with a parent molecule. Examples include, without limitation, pyridinylmethyl, pyrimidinylethyl, naphthyridinylpropyl and the like. Heteroarylalkyl groups in this document may optionally include more substituent groups on one or both parts of heteroaryl or alkyl.
[88] As noted above, preferred cyclic purine dinucleotides also include pro-drug forms of CDNs and in particular CDN thiophosphates. Pro-drugs can modify the physicochemical, biopharmaceutical and pharmacokinetic properties of drugs. Traditional pro-drugs are classified as drugs that are activated through in vivo transformation to form the active drug. Reasons for the development of the prodrug are typically poor aqueous solubility, chemical instability, low oral bioavailability, lack of blood-brain barrier penetration and high first-pass metabolism associated with the parent drug. Suitable pro-drug fractions are described in, for example, “Prodrugs and Targeted Delivery,” J. Rautico, Ed., John Wiley & Sons, 2011.
[89] The term "substantially pure" as used here with respect to cyclic purine dinucleotides refer to an Rp or Rp, Sp form that is at least 75% pure in relation to other possible stereochemicals of the chiral centers indicated in above. By way of example, a "substantially pure c-di-GMP thiophosphate Rp, Rp" would be at least 75% pure with respect to the forms Rp, Sp and Sp, Sp of c-di-GMP thiophosphate. In preferred embodiments, a substantially pure cyclic purine dinucleotide is at least 85% pure, at least 90% pure, at least 95% pure, at least 97% pure and at least 99% pure. Although a substantially pure cyclic purine dinucleotide preparation of the invention is "stereochemically pure", this should not indicate that all CDNs within the preparation having a specific stereochemistry in these chiral centers would otherwise be identical. For example, a substantially pure cyclic purine dinucleotide preparation may contain a combination of c-di-GMP thiophosphate Rp, Rp and c-di-AMP thiophosphate Rp, Rp and still be a substantially pure cyclic purine dinucleotide preparation . Such preparation may also include other components as described below, which are advantageous for the treatment of the patient, provided that all CDNs within the preparation have specific stereochemistry in these chiral centers.
[90] The CDN compositions described herein can be administered to a host, alone or in combination with a pharmaceutically acceptable excipient, in an amount sufficient to induce, modify or stimulate an appropriate immune response. The immune response can include, without limitation, specific immune response, non-specific immune response, specific and non-specific response, innate response, primary immune response, adaptive immunity, secondary immune response, immune memory response, immune cell activation, proliferation of immune cells, differentiation of immune cells and expression of cytokines. In certain embodiments, the CDN compositions are administered in conjunction with one or more additional compositions, including vaccines designed to stimulate an immune response in one or more predetermined antigens; adjuvants; CTLA-4 and PD-1 antagonists, lipids, liposomes, chemotherapeutic agents, immunomodulatory cell lines, etc.
[91] CDN compositions can be administered before, after or together with an additional therapeutic or prophylactic composition. These include, without limitation, B7 costimulation molecule, interleukin-2, interferon-Y, GM-CSF, CTLA-4 antagonists, OX-40 / OX-40 ligand, CD40 / CD40 ligand, sargramostime, levamisole, virus vaccinia, bacillus Calmette-Guérin (BCG), liposomes, alum, complete or incomplete Freund's adjuvant, detoxified endotoxins, mineral oils, surface active substances such as lipolecithin, pluronic polyols, polyanions, peptides and oil or hydrocarbon emulsions. Transporters to induce an immune response of T cells that preferentially stimulate a cytolytic response of T cells against an antibody response are preferred, although those that stimulate both types of response can be used as well. In cases where the agent is a polypeptide, the polypeptide itself or a polynucleotide that encodes the polypeptide can be administered. The carrier can be a cell, such as an antigen presenting cell (APC) or a dendritic cell. Antigen presenting cells include such cell types as macrophages, dendritic cells and B cells. Other professional antigen presenting cells include monocytes, marginal zone Kupffer cells, microglia, Langerhans cells, interdigitating dendritic cells, follicular dendritic cells and cells T. Optional antigen presenting cells can also be used. Astrocytes, follicular cells, endothelium and fibroblasts are examples of facultative antigen presenting cells. The carrier can be a bacterial cell that is transformed to express the polypeptide or deliver a polynucleotide that is later expressed in the cells of the vaccinated individual. Adjuvants, such as aluminum hydroxide or aluminum phosphate, can be added to increase the vaccine's ability to trigger, improve or prolong an immune response. Additional materials, such as cytokines and chemokines and bacterial nucleic acid sequences, such as CpG, a toll-like receptor agonist (TLR) 9 as well as additional agonists for TLR 2, TLR 4, 5 TLR, TLR 7, 8 TLR, TLR9 , including lipoprotein, LPS, monophosphoryl lipid A, lipoteichoic acid, imiquimod, resiquimod, used separately or in combination with the described compositions are also potential adjuvants. Other representative examples of adjuvants include the synthetic QS-21 adjuvant comprising a homogeneous saponin purified from the quilaia shell and Corynebacterium parvum (McCune et al, Cancer, 1979; 43: 1619). It will be understood that the adjuvant is subject to optimization. In other words, one skilled in the art can engage in routine experimentation to determine the best adjuvant to use.
[92] Methods for coadministration with an additional therapeutic agent are well known in the art (Hardman, et al. (Eds.) (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed., McGraw-Hill, New York , NY; Poole and Peterson (eds.) (2001) Pharmacotherapeutics for Advanced Practiced Practical Approach, Lippincott, Williams & Wilkins, Phila., PA; Chabner and Longo (eds.) (2001) Cancer Chemotherapy and Biotherapy, Lippincott, Williams & Wilkins, Phila., PA).
[93] Adjuvants
[94] In addition to the cyclic purine dinucleotide (s) described above, the compositions of the present invention may still include one or more additional substances that, due to their adjuvant nature, can act to stimulate the immune system to respond to cancer antigens present on inactivated tumor cells. Such adjuvants include but are not limited to lipids, liposomes, inactivated bacteria that induce innate immunity (eg, inactivated or attenuated Listeria monocytogenes), compositions that mediate innate immune activation through Toll-type receptors (TLRs), type-receptors (NOD) (NLRs), type (RIG) -I receptors based on retinoic acid-inducible genes (RLRs), and / or type C lectin receptors (CLRs). Lipoproteins, lipopolypeptides, peptidoglycans, ZnPPIX, lipopolysaccharides, neisserial porins, flagellin, profilin, galactoceramide, muramyl dipeptide are examples of PAMPs. Peptidoglycans, lipoproteins and lipoteicoic acids are components of the Gram-positive cell wall. Lipopolysaccharides are expressed by most bacteria, with MPL being an example. Flagellin refers to the structural component of bacterial flagella that is secreted by pathogenic and commensal bacteria. A-Galactosylceramide (a-GalCer) is an activator of natural killer T cells (NKT). Muramyl dipeptide is a bioactive peptidoglycan motif common to all bacteria. This list is not intended to be a limiting factor. Preferred adjuvant compositions are described below.
[95] CTLA-4 and PD-1 antagonists
[96] CTLA-4 is thought to be an important negative regulator of the adaptive immune response. Activated T cells upregulate CTLA-4, which binds CD80 and CD86 in antigen presenting cells with greater affinity than CD28, thus inhibiting T cell stimulation, IL-2 gene expression and T cell proliferation. antitumor effects of CTLA4 blockade in murine models of metastatic melanoma, metastatic prostate cancer and colon carcinoma.
[97] Ipilimumab (Yervoy ™) and tremelimumab are humanized monoclonal antibodies that bind to human CTLA4 and prevent their interaction with CD80 and CD86. Phase I and II studies using ipilimumab and tremelimumab have demonstrated clinical activity in cancer patients. Other negative immune regulators that may be the target of a similar strategy include programmed cell death 1, T and B lymphocyte attenuator, transforming beta p growth factor, interleukin-10 and vascular endothelial growth factor.
[98] PD-1 is another negative regulator of the adaptive immune response that is expressed in activated T cells. PD-1 links H1-B7 and B7-DC, and PD-1 engagement suppresses T cell activation. Anti-tumor effects have been demonstrated with PD-1 path block. BMS-936558, MK3475, CT-011, AMP-224 and MDX-1106 have been reported in the literature as examples of PD-1 pathway blockers that may find utility in the present invention.
[99] TLR Aqonistas
[100] The term "Toll-like receptor" (or "TLR") as used here refers to a member of the toll-like protein receptor family or a respective fragment that detects a microbial product and / or initiates a response adaptive immune system. In one embodiment, a TLR activates a dendritic cell (DC). Toll-type receptors (TLRs) are a family of pattern recognition receptors that were initially identified as sensors of the innate immune system that recognize microbial pathogens. TLRs comprise a conserved membrane family comprising molecules containing an ectodomain of rich leucine repeats, a transmembrane domain and an intracellular TIR domain (Toll / IL-1 R). TLRs recognize distinct structures in microbes, often referred to as "PAMPs" (pathogen associated with molecular patterns). Binding of the ligand to TLRs invokes a cascade of intracellular signaling pathways that induce the production of factors involved in inflammation and immunity.
[101] In humans, ten TLRs have been identified. TLRs that are expressed on the cell surface include TLR-1, -2, -4, -5 and -6, while TLR-3, -7/8 and -9 are expressed with the ER compartment. Subsets of human dendritic cells can be identified based on distinct patterns of TLR expression. As an example, the myeloid or "conventional" DC (mDC) subset expresses TLRs -8 when stimulated and a cascade of activation markers (for example, CD80, CD86, MHC class I and II, CCR7), cytokines pro -inflammatory and chemokines are produced. A result of this resulting stimulation and expression is initiation of antigen-specific CD4 + and CD8 + T cells. These DCs acquire a better ability to occupy antigens and present them appropriately to T cells. In contrast, the DC plasmacytoid subset (pDC) expresses only TLR7 and TLR9 after activation, with a resulting activation of NK cells, as well like T cells. Since the death of tumor cells can adversely affect DC function, it has been suggested that activating DC with TLR agonists may be beneficial for initiating antitumor immunity in an immunotherapy approach for the treatment of cancer. It has also been suggested that successful treatment of breast cancer using radiation and chemotherapy requires activation of TLR4.
[102] TLR agonists known in the art and which find use in the present invention include but are not limited to the following: Pam3Cys, a TLR-112 agonist; CFA, a TLR-2 agonist; MALP2, a TLR-2 agonist; Pam2Cys, a TLR-112 agonist; FSL-1, a TLR-2 agonist; Hib-OMPC, a TLR-2 agonist; poly ribosinic acid: polyribocytoid (poly I: C), a TLR-3 agonist; polyadenosine-polyuridyl acid (poly AU), a TLR-3 agonist; Polyinosinic-polycytidic acid stabilized with poly-L-lysine and carboxymethylcellulose (Hiltonol®), a TLR-3 agonist; monophosphoryl lipid A (MPL), a TLR-4 agonist; LPS, a TLR-4 agonist; bacterial flagellin, a TLR-5 agonist; sialyl-Tn (STn), a carbohydrate associated with mucin MUC1 in a number of human cancer cells and a TLR-4 agonist; Imiquimod, a TLR-7 agonist; resiquimod, a TLR-718 agonist; loxoribine, a TLR-7/8 agonist; and non-methylated CpG (CpG-ODN) dinucleotide, a TLR-9 agonist.
[103] Because of their adjuvant qualities, TLR agonists are preferably used in combinations with other vaccines, adjuvants and / or immune modulators and can be combined in various combinations. Thus, in certain embodiments, cyclic purine dinucleotides that bind to STING and induce activation of STK-dependent TBK1 and an inactivated tumor cell that expresses and secretes one or more cytokines that stimulate dendritic cell induction, recruitment and / or maturation, as described in this document, can be administered in conjunction with one or more TLR agonists for therapeutic purposes.
[104] Lipids and liposomes
[105] Liposomes are vesicles formed from one ("unilamellar") or more ("multilamellar") layers of phospholipids. Due to the amphipathic character of the phospholipid building blocks, liposomes usually comprise a hydrophilic layer presenting a hydrophilic outer face and enclosing a hydrophilic core. The versatility of liposomes in the modality of hydrophilic / hydrophobic components, their non-toxic nature, biodegradability, biocompatibility, adjuvanticity, induction of cellular immunity, sustained release property and rapid absorption by macrophages make them attractive candidates for the delivery of antigens.
[106] WO2010 / 104833, which is incorporated by reference in this document, in its entirety, describes liposome preparations comprising: a) an aqueous vehicle; b) liposomes comprising (i) dimyristoylphosphatidylcholine ("DMPC"), (ii) dimyristoylphosphatidylglycerol ("DMPG"), dimyristoyltrimethylammonium propane ("DMTAP"), or both DMPG and DMTAP, and (iii) at least one sterol derivative; and c) one or more immunogenic polypeptide (s) or carbohydrate (s) covalently linked to between 1% and 100% of at least one said sterol derivative.
[107] Such liposome formulations, referred to herein as VesiVax® (Molecular Express, Inc.), with or without the above "immunogenic polypeptide (s) or carbohydrate (s)", may contain one or more components additional as peptidoglycan, lipopeptide, monophosphoryl lipopolysaccharide lipid A, lipoteichoic acid, resiquimod, imiquimod, flagellin, oligonucleotides containing unmethylated CpG motifs, beta-galactosylceramide, muramyl dipeptide, double-stranded retinic acid, double-stranded protein RNA dioctadecyldimethylammonium bromide, cationic surfactants, toll-type receptor agonists, dimyristoyltrimethylammonium propane and nodal receptor agonists. Advantageously, these liposome formulations can be used to deliver one or more cyclic purine dinucleotides in accordance with the present invention.
[108] In addition, while the liposome formulations discussed above employ a "steroid derivative" as an anchor for attaching an immunogenic polypeptide or carbohydrate to a liposome, the steroid can simply be supplied as an unconjugated steroid such as cholesterol .
[109] Suitable methods for preparing liposomes from lipid mixtures are well known in the art. See, for example, Basu & Basu, Liposome Methods and Protocols (Methods in Molecular Biology), Humana Press, 2002; Gregoriadis, Liposome Technology, 3rd Edition, InformaHealthCare, 2006. Preferred methods include extrusion, homogenization and sonification methods described therein. An exemplary method for preparing liposomes for use in the present invention, which comprises drying a mixture of lipids, followed by hydration in an aqueous vehicle and sonification to form liposomes, is described in WO2010 / 104833.
[110] In certain embodiments, liposomes are delivered within a specific range of medium size. Liposome size can be selected, for example, by extruding an aqueous vehicle comprising liposomes through membranes with a pre-selected pore size and collecting the material flowing through the membrane. In preferred embodiments, the liposomes are selected to be substantially between 50 and 500 nm in diameter, more preferably substantially between 50 and 200 nm in diameter and most preferably substantially between 50 and 150 nm in diameter. The term "substantially" as used herein in this context means that at least 75%, more preferably 80% and most preferably at least 90% of the liposomes are within the designated range.
[111] Other lipids and lipid-like adjuvants that may find use in the present invention include oil-in-water (o / w) emulsions (see, for example, Muderhwa et al, J. Pharmaceut. Sci. 88: 1332-9 , 1999)), VesiVax® TLR (Molecular Express, Inc.), digitonin (see, for example, US Patent 5,698,432), and glucopyranosyl lipids (see, for example, US Patent Application 20100310602).
[112] Chemotherapy Agents
[113] In additional modalities the methods still involve administering to the subject an effective amount of one or more chemotherapeutic agents as an additional treatment. In certain modalities, one or more chemotherapeutic agents are selected from abiraterone acetate, altretamine, anhydrovinblastine, auristatin, bexarotene, bicalutamide, BMS 184476, 2,3,4,5,6-pentafluor-N- (3-fluor-4-methoxyphenyl) benzene sulfonamide, bleomycin, N, N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-proli-1-Lproline-t-butylamide, caquetina, cemadotine, chlorambucil, cyclophosphamide, S '^ '-didehydro ^' - deoxy-S'-norvin- kaleucoblastine, docetaxol, doxetaxel, cyclophosphamide, carboplatin, carmustine, cisplatin, cryptophine, cyclophosphamide, cytarabine, dacarbazine (DTIC), dactinomycin, dyrycinine, daitorhinubicin, dainorubin, etoposide, 5-fluorouracil, finasteride, flutamide, hydroxyurea and hydroxyureataxanes, ifosfamide, liarozole, lonidamine, lomustine (CCNU), MDV3100, meclorethamine (mustard nitrogen), melphalan, mivobulin isethionate, methydehydrocephate, methydehydrogeoxin, taxidermyzone, taxis , nilutamide, onapristone, pacli taxel, prednimustine, procarbazine, RPR109881, stramustine phosphate, tamoxifen, tasonermin, taxol, tretinoin, vinblastine, vincristine, vindesine sulfate and vinflunine.
[114] Immunomodulatory Cell Lines
[115] By "tumor cell inactivated" is meant a tumor cell ("autologous" or "allogeneic" to the patient) that has been treated to prevent cell division. For the purposes of the present invention, such cells preserve their immunogenicity and metabolic activity. Such tumor cells are genetically modified to express a transgene that is expressed within a patient as part of cancer therapy. Thus, a composition or vaccine of the invention comprises neoplastic cells (e.g., tumor) that are autologous or allogeneic to the patient being treated and most preferably are of the same general type as the tumor cell that afflicts the patient. For example, a patient suffering from melanoma will usually be given a genetically modified cell derived from a melanoma. Methods for inactivating tumor cells for use in the present invention, such as the use of irradiation, are well known in the art.
[116] The inactivated tumor cells of the present invention are administered to the patient in conjunction with one or more costimulation molecules or agents. A preferred costimulation agent is composed of one or more cytokines that stimulate dendritic cell induction, recruitment and / or maturation. Methods for evaluating such costimulation agents are known in the literature. Induction and maturation of DCs is usually assessed by increasing the expression of certain membrane molecules such as CD80 and CD86, and / or secretion of pro-inflammatory cytokines, such as IL-12 and type I interferons after stimulation.
[117] In preferred embodiments, the inactivated tumor cells themselves are modified to express and secrete one or more cytokines that stimulate dendritic cell induction, recruitment and / or maturation. The present invention is described in exemplary terms with respect to the use of GM-CSF. Thus, by way of example, the tumor cell can express a transgene encoding GM-CSF, as described in Pat. No. 5,637,483, 5,904,920, 6,277,368 and 6,350,445, as well as U.S. Patent Publication No. 20100150946, each of which is expressly incorporated by reference herein. A form of genetically modified cancer cells that express GM-CSF or a "cell vaccine that expresses cytokine" for the treatment of pancreatic cancer is described in Pat. Nos. 6,033,674 and 5,985,290, both of which are expressly incorporated by reference in this document.
[118] Other suitable cytokines that can be expressed from such inactivated tumor cells and / or spectator cells instead of, or in conjunction with, GM-CSF include, but are not limited to one or more of the CD40, IL-12, CCL3, CCL20 and CCL21. This list is not intended to be a limiting factor.
[119] While it is preferable that the inactivated tumor cells administered to the subject express one or more cytokines of interest, the tumor cell line can be accompanied by an inactivated spectator cell line that expresses and secretes one or more cytokines that stimulate induction of dendritic cells, recruitment and / or maturation. The viewer's cell line can provide all cytokines that stimulate dendritic cell induction, recruitment and / or maturation, or they can supplement cytokines that stimulate dendritic cell induction, recruitment and / or maturation expressed and secreted by tumor inactivated cells . For example, immunomodulatory spectator cell lines that express cytokine are disclosed in U.S. Pat. Nos. 6,464,973 and 8,012,469, Dessureault et al., Ann. Surg. Oncol. 14: 869-84, 2007, and Eager and Nemunaitis, Mol. Ther. 12: 18-27, 2005, each of which is expressly incorporated by reference in this document.
[120] By "granulocyte-macrophage colony stimulating factor polypeptide (GM-CSF)" is meant a cytokine or respective fragment with immunomodulatory activity and at least about 85% amino acid sequence identity with GenBank Adhesion No. AAA52122.1.
[121] Vaccines
[122] In certain embodiments, CDN compositions are administered in conjunction with one or more vaccines designed to stimulate an immune response to one or more predetermined antigens. Examples of target antigens that can find use in the invention are listed in the following table. The target antigen can also be a fusion fragment or polypeptide comprising an immunologically active portion of the antigens listed in the table. This list is not intended to be a limiting factor. Table 1: Antigens.













Other organisms for which suitable antigens are known in the art include, but are not limited to, Chlamydia trachomatis, Streptococcus pyogenes (Group A Strep), Streptococcusagalactia (Group B Strep), Streptococcus pneumonia, Staphylococcus aureus, Escherichia coli, Haemophilisingusi , Neisseria gonorrheae, Vibrio cholerae, Salmonella species (including typhi, typhimurium), enterica (including Helicobactor pylori Shigella flexneri and other Group D shigella species), Burkholderiamallei, Burkholderia pseudomallei, Klebsiella pneumonia, Clostricile species (including C. diff ), Vibrio parahaemolyticus and V. vulnificus. This list is not intended to be a limiting factor.
[123] Pharmaceutical Compositions
[124] The term "pharmacist" in this document refers to a chemical substance intended for use in the cure, treatment or prevention of disease and which is subject to an approval process by the US Food and Drug Administration (or an equivalent outside the US ) as a prescription or over-the-counter drug product. Details on techniques for formulating and administering such compositions can be found in Remington, The Science and Practice of Pharmacy 21st Edition (Mack Publishing Co., Easton, PA) and Nielloud and Marti-Masters, Pharmaceutical Emulsions and Suspensions: 2nd Edition ( Marcel Dekker, Inc, New York).
[125] For disclosure purposes, pharmaceutical compositions can be administered by a variety of means, including orally, parenterally, inhalation spray, topically, or rectally in formulations containing pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used here includes but is not limited to subcutaneous, intravenous, intramuscular, intraarterial, intradermal, intrathecal and epidural injections with a variety of infusion techniques. Intravenous and intra-arterial injection in this document includes administration through catheters. Administration via intracoronary stents and intracoronary reservoirs is also contemplated. The oral term in this document includes, but is not limited to, oral ingestion, or sublingual or buccal delivery. Oral administration includes fluid drinks, energy bars, as well as pill formulations.
[126] Pharmaceutical compositions can be in any form suitable for the intended method of administration. When used for oral use, for example, tablets, lozenges, sucking tablets, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs can be prepared. Compositions intended for oral use can be prepared according to any method known in the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide pharmaceutically palatable preparations. Pills containing the drug compound in the mixture with non-toxic pharmaceutically acceptable excipients, which are suitable for the manufacture of tablets, are acceptable. Such excipients can be, for example, inert diluents, such as calcium or sodium carbonate, lactose, calcium or sodium phosphate; granulating and disintegrating agents, such as corn starch or alginic acid; binding agents, such as starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. The tablets can be uncoated or can be coated by known techniques including enteric coating, colonic coating and microencapsulation to delay disintegration and absorption in the gastrointestinal tract and / or provide sustained action over a longer period. For example, a time-delaying material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, can be employed.
[127] Formulations for oral use can also be presented as hard gelatin capsules in which the drug compound is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or soft gelatin capsules, wherein the active ingredient is mixed with a water-soluble carrier such as polyethylene glycol or an oil medium, for example peanut oil, liquid paraffin or olive oil.
[128] Pharmaceutical compositions can be formulated as aqueous suspensions in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include a suspending agent, such as sodium carboxymethylcellulose, croscarmellose, povidone, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, tragacanth and gum arabic, and dispersing or humidifying agents, such as naturally occurring phosphatide (for example, lecithin), a condensation product of an alkylene oxide with a fatty acid (for example, polyoxyethylene stearate), a condensation product of ethylene oxide with a long-chain aliphatic alcohol (for example, heptadecaethylene-oxyethanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (for example, polyoxyethylene sorbitan monooleate). Aqueous solutions can also contain one or more preservatives, such as n-propyl ethyl or p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose or saccharin.
[129] Oily suspensions can be formulated by suspending the active ingredient (s) in a vegetable oil, for example, arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as like liquid paraffin. Oral suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those defined above and flavoring agents can be added to provide a palatable oral preparation. These compositions can be preserved by the addition of an antioxidant such as ascorbic acid.
[130] Dispersible powders and granules of the disclosure suitable for the preparation of an aqueous solution or suspension by the addition of water provide the active ingredient in the mixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersants or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweeteners, flavorings and coloring agents, may also be present.
[131] The pharmaceutical compositions of the disclosure can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifying agents include naturally occurring gums, such as acacia and tragacanth gum, naturally occurring phosphatides, such as soy lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion can also contain sweetening and flavoring agents.
[132] Syrups and elixirs can be formulated with sweetening agents, such as glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavoring or coloring agents.
[133] The pharmaceutical compositions of the disclosure may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated according to the known technique using suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butanediol or prepared as a lyophilized powder. Among the acceptable vehicles and solvents that can be used are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils can conventionally be used as a solvent or suspending medium. For this purpose, any soft, fixed oil can be used including synthetic mono- or diglycerides. In addition, fatty acids, such as oleic acid, can be used in the same way in the preparation of injectables.
[134] The amount of active ingredient that can be combined with the carrier material for the purpose of producing a unit dosage form will vary depending on the treated host and the specific mode of administration. For example, a time-release formulation intended for oral administration to humans may contain approximately 20 to 500 mg of active material composed of an appropriate and convenient amount of carrier material, which can vary from about 5 to about 95% of the total compositions. It is preferred that the pharmaceutical composition is prepared that provides readily measurable amounts for administration. Typically, an effective amount to be administered systemically is approximately 0.1 mg / kg to about 100 mg / kg and depends on a number of factors, including, for example, the subject's age and weight (for example, a mammal like a human being), the precise condition that requires treatment and its severity, the route of administration, and will ultimately be at the discretion of the attending physician or veterinarian. It will be understood, however, that the specific dose level for any particular patient will depend on a variety of factors, including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the individual to be treated; the time and route of administration; the rate of excretion; other drugs that were previously administered; and the severity of the specific condition in therapy, as is well understood by those skilled in the art.
[135] As noted above, formulations of the disclosure suitable for oral administration can be presented as discrete units such as capsules, pills or lozenges, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The pharmaceutical compositions can also be administered as a bolus, electuary or paste.
[136] A tablet can be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing, in a suitable machine, the active principle in a free-flowing form, such as a powder or granules, optionally mixed with binders (eg povidone, gelatin, hydroxypropylmethyl cellulose), inert diluents, preservative , disintegrant (eg sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) or lubricating agents, active or dispersing surface. Molded tablets can be made by shaping, in a suitable machine, using a mixture of the powdered compound moistened with an inert liquid diluent. The tablets can optionally be coated or labeled and can be formulated to provide slow or controlled release of the active ingredient in them using, for example, hydroxypropyl methylcellulose, in varying proportions to provide the desired release profile. Tablets can optionally be provided with an enteric or colonic coating to provide release in parts of the intestine other than the stomach. This is particularly advantageous with the compounds of Formula 1, when such compounds are susceptible to acid hydrolysis.
[137] Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored base, usually sucrose and acacia or tragacanth; lozenges, comprising the active ingredient in an inert base such as gelatin and glycerin, or sucrose and acacia; and mouthwash containing the active ingredient in an appropriate liquid carrier.
[138] Formulations for rectal administration can be presented as a suppository with a suitable base, which comprises, for example, cocoa butter or a salicylate.
[139] Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient these carriers as are known in the art to be appropriate.
[140] Formulations suitable for parenteral administration include sterile aqueous and non-aqueous isotonic injection solutions that may contain antioxidants, buffers, bacteriostats and solutes that make the formulation isotonic with the intended recipient's blood; and sterile aqueous and non-aqueous suspensions which may include suspending agents and thickening agents. The formulations can be presented in sealed single-dose or multiple-dose containers, for example, ampoules and vials and can be stored in a dry (freeze-dried) condition, requiring only the addition of the sterile liquid carrier, for example, water for injections, just before use. Injection solutions and suspensions can be prepared from sterile powders, granules and tablets of the type described above.
[141] As used herein, pharmaceutically acceptable salts include, but are not limited to: acetate, pyridine, ammonium, piperazine, diethylamine, nicotinamide, formic, urea, sodium, potassium, calcium, magnesium, zinc, lithium, cinnamic, methylaminosulfonic , picric, tartaric, triethylamino, dimethylamino and tris (hydroxymethyl) aminomethane. Additional pharmaceutically acceptable salts are known to those skilled in the art.
[142] An effective amount for a given patient can vary depending on factors such as the condition being treated, the general health of the patient, the route and dose of administration, and the severity of side effects. Guidance for diagnostic and treatment methods is available (See, for example, Maynard, et al. (1996) A Handbook of SOPs for Good Clinical Practice, Interpharm Press, Boca Raton, FL; Dent (2001) Good Laboratory and Good Clinical Practice, Urch Publ., London, UK).
[143] An effective amount can be given in one dose, but is not restricted to one dose. Thus, the administration can be two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty or more administrations of the pharmaceutical composition. Where there is more than one administration of a pharmaceutical composition in the present methods, the administrations may be spaced apart by time intervals of one minute, two minutes, three, four, five, six, seven, eight, nine, ten or more minutes, by intervals of about an hour, two hours, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 hours, and so on. In the context of hours, the term "about" means more or less any time interval within 30 minutes. Administrations can also be spaced by time intervals of one day, two days, three, four days, five, six days, seven, eight days, nine, ten days, days 11, 12 days, days 13, 14 days, 15 days, 16, 17 days, 18, 19 days, 20 days, 21 days and their combinations. The invention is not limited to dosage intervals that are spaced equally in time, but encompasses doses at unequal intervals.
[144] A dosing schedule of, for example, once / week, twice a week, three times / week, four times / week, five times / week, six times / week, seven times / week, once a every two weeks, once every three weeks, once every four weeks, once every five weeks and the like is available for the invention. Dosing schedules encompass dosing over a total period of time, for example, one week, two weeks, three weeks, four weeks, five weeks, six weeks, two months, three months, four months, five months, six months , seven months, eight months, nine, ten months, eleven months and twelve months.
[145] Cycles of the above dosing schedules are provided. The cycle can be repeated about, for example, every seven days; every 14 days; every 21 days; every 28 days; every 35 days; 42 days; every 49 days; every 56 days; every 63 days; every 70 days; and others. A non-dosage interval can occur between a cycle, where the interval can be, for example, seven days; 14 days; 21 days; 28 days; 35 days; 42 days; 49 days; 56 days; 63 days; 70 days; and others. In this context, the term "about" means more or less one day, more or less two days, more or less three days, more or less four days, more or less five days, more or less six days, or more or less seven days.
[146] Methods for coadministration with an additional therapeutic agent are well known in the art (Hardman, et al. (Eds.) (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed., McGraw-Hill, New York , NY; Poole and Peterson (eds.) (2001) Pharmacotherapeutics for Advanced Practice: A Practical Approach, Lippincott, Williams & Wilkins, Phila., PA; Chabner and Longo (eds.) (2001) Cancer Chemotherapy and Biotherapy, Lippincott, Williams & Wilkins, Phila., PA).
[147] As noted, the compositions of the present invention are preferably formulated as pharmaceutical compositions for parenteral or enteral delivery. A typical pharmaceutical composition for administration to an animal comprises a pharmaceutically acceptable carrier as aqueous solutions, toxic excipients, including salts, preservatives, tampons and the like. See, for example, Remington's Pharmaceutical Sciences, 15th Ed., Easton ed. , Mack Publishing Co., pp 1405-1412 and 1461-1487 (1975); The National Formulary XIV, 14th Ed., American Pharmaceutical Association, Washington, DC (1975). Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters, such as ethyl oleate. Aqueous carriers include water, aqueous / alcoholic solutions, saline solutions, parenteral vehicles, such as sodium chloride, Ringer's dextrose, etc. Intravenous vehicles include fluid and nutrient stores. Preservatives include antimicrobial agents, antioxidants, chelating agents and inert gases. The pH and the exact concentration of the various components of the pharmaceutical composition are adjusted according to ordinary skill in the art.
[148] Repeated administrations of a given vaccine (year-on-year increase) have been shown to be effective in boosting humoral responses. This approach may not be effective in increasing cellular immunity because immunity prior to the vector tends to impair the presentation of robust antigens and the generation of appropriate inflammatory signals. One approach to circumvent this problem has been the sequential administration of vaccines that use delivery systems other than the antigen (heterologous increment). In a heterologous increment regimen, at least one initiated or increment delivery comprises delivery of the cyclic purine dinucleotide / inactivated tumor cell compositions described herein. The heterologous branch of the regimen may include delivery of the antigen, using one or more of the following strategies: inactivated or attenuated bacteria or viruses that comprise the antigen of interest, which are particles that have been treated with some condition of denaturation to render them ineffective or inefficient in a pathogenic invasion; purified antigens, which are normally produced naturally purified antigens from a cell culture of the pathogen or a tissue sample containing the pathogen, or a recombinant version Live viral or bacterial delivery vectors recombinantly designed to express and / or secrete antigens in the host cells of the subject. These strategies depend on attenuating (for example, through genetic engineering) viral or bacterial vectors in order to be non-pathogenic and non-toxic; antigen-presenting cell (APC) vectors, such as a dendritic cell (DC) vector, which comprises cells that are loaded with an antigen, or transfected with a composition that comprises a nucleic acid encoding the antigen (for example, Provenge® (Dendreon Corporation) for the treatment of castration-resistant metastatic prostate cancer); liposomal antigen delivery vehicles; and naked DNA vectors and naked RNA vectors, which can be administered by a gene injector, electroporation, bacterial ghosts, microspheres, microparticles, liposomes, polycationic nanoparticles and the like.
[149] An initiation vaccine and an increment vaccine can be administered by either or a combination of routes to follow. In one aspect, the first vaccine and increment vaccine are administered by the same route. In another aspect, the initiation vaccine and the increment vaccine are administered by different routes. The term "different routes" includes, but is not limited to, different sites on the body, for example, a site that is oral, non-oral, enteral, parenteral, rectal, intranode (lymph node), intravenous, arterial, subcutaneous, intramuscular, intratumor, peritumor, intratumor, infusion, mucosa, nasal, in the cerebrospinal space or cerebrospinal fluid, and so on, as well as in different ways, for example, oral, intravenous and intramuscular.
[150] An effective amount of an initiation or increment vaccine can be given in one dose, but is not restricted to one dose. Thus, administration can be two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty or more vaccine administrations. Where there is more than one administration of a vaccine in the present methods, the administrations may be spaced by one-minute, two-minute, three, four, five, six, seven, eight, nine, ten or more time intervals about an hour, two hours, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 , 24 hours, and so on. In the context of hours, the term "about" means more or less any time interval within 30 minutes. Administrations can also be spaced by time intervals of one day, two days, three, four days, five, six days, seven, eight days, nine, ten days, 11.12 days, days 13, 14 days, 15 days, 16, 17 days, 18, 19 days, 20 days, 21 days and their combinations. The invention is not limited to dosage intervals that are spaced equally in time, but encompasses doses at uneven intervals, such as an initiation schedule consisting of administration in 1 day, 4 days, 7 days and 25 days, just to provide a example of non-limitation.
[151] References 1 Reed, S. G., Bertholet, S., Color, R. N. & Friede, M. New horizons in adjuvants for vaccine development. Trends in immunology 30, 23-32, doi: 10.1016 / j.it.2008.09.006 (2009). 2 Dubensky, T. W., Jr. & Reed, S. G. Adjuvants for cancer vaccines. Seminars in immunology 22, 155-161, doi: 10.1016 / j.smim.2010.04.007 (2010). 3 Kastenmuller, K. et al. Protective T cell immunity in mice following protein-TLR7 / 8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. The Journal of clinical investigation 121, 1782-1796, doi: 10.1172 / JCI45416 (2011). 4 Coffman, R. L, Sher, A. & Seder, R. A. Vaccine adjuvants: putting innate immunity to work. Immunity 33, 492-503, doi: 10.1016 / j.immuni.2010.10.002 (2010). 5 Burdette, D. L. et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature 478, 515-518, doi: 10.1038 / nature10429 (2011). 6 Woodward, J. J., lavarone, A. T. & Portnoy, D. A. c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response. Science 328, 1703-1705, doi: 10.1126 / science.1189801 (2010). 7 Ishikawa, H. & Barber, G. N. STING is an endoplasmic reticulum adapter that facilitates innate immune signalling. Nature 455, 674-678, doi: 10.1038 / nature07317 (2008). 8 McWhirter, S. M. et al. A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. The Journal of experimental medicine 206, 1899-1911, doi: 10.1084 / jem.20082874 (2009). 9 Bahjat, K. S. et al. (2005). 10 Bahjat, K. S. et al. Cytosolic Entry Controls CD8 + -T-Cell Potency during Bacterial Infection. Infection and immunity 74, 6387-6397 (2006). 11 Crimmins, G. T. et al. Listeria monocytogenes multidrug resistance transporters activate a cytosolic surveillance pathway of innate immunity. Proceedings of the National Academy of Sciences of the United States of America (2008). 12 O'Riordan, M., Yi, C. H., Gonzales, R., Lee, K. D. & Portnoy, D. A. Innate recognition of bacteria by a macrophage cytosolic surveillance pathway. Proceedings of the National Academy of Sciences of the United States of America 99, 13861-13866 (2002). 13 Schwartz, K. T. et al. Hyperinduction of host beta interferon by a Listeria monocytogenes strain naturally overexpressing the multidrug efflux pump MdrT. Infection and immunity 80, 1537-1545, doi: 10.1128 / IAI.06286-11 (2012). 14 Davies, B. W., Bogard, R. W., Young, T. S. & Mekalanos, J. J. Coordinated regulation of accessory genetic elements produces cyclic dinucleotides for V. cholerae virulence. Cell 149, 358-370, doi: 10.1016 / j.cell.2012.01.053 (2012). 15 Witte, C. E. et al. Innate immune pathways triggered by Listeria monocytogenes and their role in the induction of cell-mediated immunity. Advances in immunology 113, 135-156, doi: 10.1016 / B978-0-12-394590- 7.00002-6 (2012). 16 Desmet, C. J. & Ishii, K. J. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nature reviews. Immunology 12, 479-491, doi: 10.1038 / nri3247 (2012). 17 Rappuoli, R., Mandi, C. W., Black, S. & De Gregorio, E. Vaccines for the twenty-first century society. Nature reviews. Immunology 11, 865872, doi: 10.1038 / nri3085 (2011). 18 Iwasaki, A. & Medzhitov, R. Regulation of adaptive immunity by the innate immune system. Science 327, 291-295, doi: 10.1126 / science.1183021 (2010). 19 Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature immunology 11, 373384, doi: 10.1038 / ni. 1863 (2010). 20 Einstein, M. H. et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Human vaccines 5, 705-719 (2009). 21 Ahmed, S. S., Plotkin, S. A., Black, S. & Coffman, R. L. Assessing the safety of adjuvanted vaccines. Science translational medicine 3, 93rv92, doi: 10.1126 / scitranslmed.3002302 (2011). 22 Vance, R. E., Isberg, R. R. & Portnoy, D. A. Patterns of pathogenesis: discrimination of pathogenic and nonpathogenic microbes by the innate immune system. Cell host & microbe 6, 10-21, doi: 10.1016 / j.chom.2009.06.007 (2009). 23 Barber, G. N. STING-dependent signaling. Nature immunology 12, 929-930, doi: 10.1038 / ni.2118 (2011). 24 Leber, J. H. et al. Distinct TLR- and NLR-mediated transcriptional responses to an intracellular pathogen. PLoS pathogens 4, e6 (2008). 25 Jin, L. et al. MPYS is required for IFN response factor 3 activation and type I IFN production in the response of cultured phagocytes to bacterial second messengers cyclic-di-AMP and cyclic-di-GMP. J Immunol 187, 2595-2601, doi: 10.4049 / jimmunol. 1100088 (2011). 26 Lauvau, G. et al. Priming of memory but not effector CD8 T cells by a killed bacterial vaccine. Science 294, 1735-1739 (2001). 27 Bahjat, K. S. et al. Suppression of cell-mediated immunity following recognition of phagosome-confined bacteria. PLoS pathogens 5, e1000568, doi: 10.1371 /journal.ppat. 1000568 (2009). 28 Tamayo, R., Pratt, J. T. & Camilli, A. Roles of cyclic diguanylate in the regulation of bacterial pathogenesis. Annual review of microbiology 61, 131-148, doi: 10.1146 / annurev.micro.61.080706.093426 (2007). 29 Sauer, J. D. et al. The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infection and immunity 79, 688-694, doi: 10.1128 / IAI.00999-10 (2011). 30 Barber, G. N. Cytoplasmic DNA innate immune pathways. Immunological reviews 243, 99-108, doi: 10.1111 / j.1600-065X.2011.01051.x (2011). 31 Tanaka, Y. & Chen, Z. J. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Science signaling 5, ra20, doi: 10.1126 / scisignal.2002521 (2012). 32 Ebensen, T. et al. Bis- (3 ', 5') - cyclic dimeric adenosine monophosphate: strong Th1 / Th2 / Th17 promoting mucosal adjuvant. Vaccine 29, 5210-5220, doi: 10.1016 / j.vaccine.2011.05.026 (2011). 33 Ebensen, T. et al. The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties. Vaccine 25, 1464-1469, doi: 10.1016Zj.vaccine.2006.10.033 (2007). 34 Ebensen, T., Schulze, K., Riese, P., Morr, M. & Guzman, C. A. The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant. Clinical and vaccine immunology: CVI 14, 952-958, doi: 10.1128 / CVI.00119-07 (2007). 35 Libanova, R. et al. The member of the cyclic di-nucleotide family bis- (3 ', 5') - cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant. Vaccine 28, 2249-2258, doi: 10.1016 / j.vaccine.2009.12.045 (2010). 36 Madhun, A. S. et al. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4 + cells and strong mucosal and systemic antibody responses in mice. Vaccine 29, 4973-4982, doi: 10.1016 / j.vaccine.2011.04.094 (2011). 37 Hu, D. L. et al. c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection. Vaccine 27, 4867-4873, doi: 10.1016 / j.vaccine.2009.04.053 (2009). 38 Karaolis, D. K. et al. Cyclic di-GMP stimulates protective innate immunity in bacterial pneumonia. Infection and immunity 75, 4942-4950, doi: 10.1128 / IAI.01762-06 (2007). 39 Ogunniyi, A. D. et al. c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection. Vaccine 26, 4676- 4685, doi: 10.1016 / j.vaccine.2008.06.099 (2008). 40 Karaolis, D. K. et al. Bacterial c-di-GMP is an immunostimulatory molecule. J Immunol 178, 2171-2181 (2007). 41 Wille-Reece, U. et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. The Journal of experimental medicine 203, 1249-1258 (2006). 42 Adler-Moore, J. et al. Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine. Vaccine 29, 44604468, doi: 10.1016 / j.vaccine.2011.04.040 (2011). 43 Fujii, G., Ernst, W. & Adler-Moore, J. The VesiVax system: a method for rapid vaccine development. Frontiers in bioscience: a journal and virtual library 13, 1968-1980 (2008). 44 Gaffney, B. L, Veliath, E., Zhao, J. & Jones, R. A. One-flask syntheses of c-di-GMP and the [Rp, Rp] and [Rp, Sp] thiophosphate analogues. Organic letters 12, 3269-3271, doi: 10.1021 / ol101236b (2010). 45 Zhang, z., Garrido, B. L. & Jones, r. a, c-di-GMP exhibits a monovalent metal ion dependent polymorphism. Journal of the American Chemical Society 126, 16700-16701, doi: 10.1021 / ja0449832 (2004). 46 Suzuki, N., Oyama, K.-i. & Tsukamoto, M. Practical Synthesis of Cyclic Bis (3'-5 ') diadenylic Acid (c-di-AMP). Chemistry Letters 40, 11131114, doi: 10.1246 / CI.2011.1113 (2011). 47 Hyodo, M., Sato, Y. & Hayakawa, Y. Synthesis of cyclic bis (3'-5 ') diguanylic acid (c-di-GMP) analogs. Tetrahedron 62, 3089-3094, doi: 10.1016 / j.tet.2006.01.025 (2006). 48 Yan, H., Wang, X., KuoLee, R. & Chen, W. Synthesis and immunostimulatory properties of the phosphorothioate analogues of cdiGMP. Bioorganic & medicinal chemistry letters 18, 5631-5634, doi: 10.1016 / j.bmcl.2008.08.088 (2008). 49 Ross, P. et al. The cyclic diguanylic acid regulatory system of cellulose synthesis in Acetobacter xylinum. Chemical synthesis and biological activity of cyclic nucleotide dimer, trimer, and phosphothioate derivatives. The Journal of biological chemistry 265, 18933-18943 (1990). 50 Grajkowski, A., Cieslak, J., Gapeev, A., Schindler, C. & Beaucage, S. L. Convenient synthesis of a propargylated cyclic (3'-5 ') diguanylic acid and its "click" conjugation to a biotinylated azide. Bioconjugate chemistry 21, 2147-2152, doi: 10.1021 / bc1003857 (2010). 51 Zhao, J., Veliath, E., Kim, S., Gaffney, B. L. & Jones, R. A. Thiophosphate analogs of c-di-GMP: impact on polymorphism. Nucleosides, nucleotides & nucleic acids 28, 352-378, doi: 10.1080 / 15257770903044523 (2009). 52 Battistini, C., Fustinoni, S., Brasca, M. & Borghi, D. Stereoselective synthesis of cyclic dinucleiotide phosphorothioates. Tetrahedron, 1115-1132 (1993). 53 Hayakawa, Y. A facile synthesis of cyclic bis (3 '-> 5') diguanylic acid. Tetrahedron 59, 6465-6471, doi: 10.1016 / s0040-4020 (03) 01045-7 (2003). 54 Coughlin, J. E. et al. Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugs. Bioorganic & medicinal chemistry letters 20, 17831786, doi: 10.1016 / j.bmcl.2010.01.010 (2010). 55 Ouyang, S. et al. Structural Analysis of the STING Adapter Protein Reveals a Hydrophobic Dimer Interface and Mode of Cyclic di-GMP Binding. Immunity, doi: 10.1016 / j.immuni.2012.03.019 (2012). 56 Baldwin, S. L. et al. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol 188, 2189-2197, doi: 10.4049 / jimmunol. 1102696 (2012). 57 Lee, A. W. et al. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 20 Suppl 4, A8-A22 (2002). 58 Lubong Sabado, R. et al. In vitro priming recapitulates in vivo HIV-1 specific T cell responses, revealing rapid loss of virus reactive CD4 T cells in acute HIV-1 infection. PloS one 4, e4256, doi: 10.1371 / journal.pone.0004256 (2009). 59 Skoberne, M. et al. KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity. The Journal of clinical investigation (2008). 60 Jin, L. et al. Identification and characterization of a loss-of-function human MPYS variant. Genes and immunity 12, 263-269, doi: 10.1038 / gene.2010.75 (2011). 61 Schmidt, N. W. et al. Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proceedings of the National Academy of Sciences of the United States of America 105, 14017-14022 (2008). 62 Pham, N. L. et al. Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly. Proceedings of the National Academy of Sciences of the United States of America 107, 12198-12203, doi: 10.1073 / pnas.1004661107 (2010). 63 Badovinac, V. P., Messingham, K. A., Jabbari, A., Haring, J. S. & Harty, J. T. Accelerated CD8 + T-cell memory and prime-boost response after dendritic-cell vaccination. Nature medicine 11,748-756 (2005). 64 Harty, J. T. & Badovinac, V.P. Shaping and reshaping CD8 + T-cell memory. Nature reviews. Immunology 8, 107-119 (2008). 65 Coler, R. N. et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PloS one 6, e16333, doi: 10.1371 / journal.pone.0016333 (2011). 66 Singh, S., Briles, W. E., Lupiani, B. & Collisson, E. W. Avian viral influenza nucleocapsid and hemagglutinin proteins induce chicken CD8 + memory T lymphocytes. Virology 399, 231-238, doi: 10.1016 / j.virol.2009.12.029 (2010). 67 Singh, S. et al. Non-replicating adenovirus vectors expressing avian influenza virus hemagglutinin and nucleocapsid proteins induce chicken specific effector, memory and effector memory CD8 (+) T lymphocytes. Virology 405, 62-69, doi: 10.1016 / j.virol.2010.05.002 (2010). 68 Tewari, K. et al. Poly (l: C) is an effective adjuvant for antibody and multi-functional CD4 + T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates. Vaccine 28, 7256-7266, doi: 10.1016 / j.vaccine.2O10.08.098 (2010). 69 Wille-Reece, U. et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8 + T cell responses in nonhuman primates. Proceedings of the National Academy of Sciences of the United States of America 102, 15190-15194, doi: 10.1073 / pnas.0507484102 (2005). 70 Seder, R. A., Darrah, P. A. & Roederer, M. T-cell quality in memory and protection: implications for vaccine design. Nature reviews. Immunology 8, 247-258 (2008). 71 Wille-Reece, U., Wu, C. Y „Flynn, BJ, Kedl, RM & Seder, RA Immunization with HIV-1 Gag protein conjugated to a TLR7 / 8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8 + T cell responses. J Immunol 174, 7676-7683 (2005). 72 Jones et al., US20120178710. EXAMPLES
[152] The following examples are given to illustrate the present invention. These examples are not intended to restrict the scope of the invention in any way.
[153] Example 1: General Methods
[154] Anhydrous solvents and reagents suitable for synthesis of solution phase oligonucleotides were purchased and manipulated under dry argon or nitrogen, using the anhydrous technique. Amidite coupling reactions and cyclizations were performed in anhydrous acetonitrile or pyridine under argon or dry nitrogen. The raw materials for all dry pyridine reactions were dried by concentration (three times) from pyridine. Preparative silica gel chromatography was performed using high purity grade Fluka 60A or Merck grade 9385 silica using methanol in dichloromethane gradients. Analytical HPLC was performed on a Varian ProStar 210 HPLC system with a ProStar 330 photodiode matrix detector monitoring at 254nm on a Varian Microsorb C 100-1018 250x4.6mm column using 10mm TEAA and acetonitrile gradients at a flow rate of 1.0 ml / min . Preparative HPLC was performed on a Shimadzu LC20-AP preparative HPLC system, equipped with an SPD-20A UV / Vis detector monitoring at 254nm on a 41.6 x 250mm 18 Varian Microsorb 608 C column using 10mm gradients of TEAA and acetonitrile over a flow rate of 50 ml / min. Solid phase extractions using C-18 Sep-Pak (Waters) were performed at ~ 3% (weight / weight) loads. LC / MS (ESI / APCI) was obtained in a single Shimadzu 2010 EV quadrapole instrument with PDA, MS and ELSD detection using a Shimadzu LC20D analytical HPLC. A high-resolution FT-ICR mass spectrometer was obtained from the WM Keck Foundation Biotechnology Resource Laboratory at Yale University in New Haven, CT. The PMNR spectra 1h and 31 were acquired in a Bruker 400 MHz spectrometer or a Varian Inova 500 MHz spectrometer. PNMR 31 were indirectly referred to dioxane in D2O.
[155] The assignment of purified cyclic dinucleotides and HPLC derivatives are summarized in Table 1 and described in detail in the examples. Table 1: Retention time in Reverse Phase HPLC (min) and Chemical Changes 31P (ppm) at 25 'C of triethylammonium salts (10a, 10b, 10c, 11a, 11b, 11c, 12, 13)
'HPLC gradient: 2 to 20% CH3CN in 10mM TEAA for 20 min at a flow of 1ml / min §HPLC gradient: 2 to 80% CH3CN in 10mM TEAA for 20 min at a flow of 1ml / min
[156] Example 2. Synthesis of 10a.
[157] The following cyclic-di-AMP synthesis is described schematically in Fig. 6 and is a modification of a cyclic-di-GMP synthesis reported by Gaffney et al. (One-flask synthesis of c-di-GMP and the [Rp, Rp] and [Rp, Sp] thiophosphate analogues. Organic Letters 12, 3269-3271 (2010)).
[158] a) Phosphorylation of 1 with 2-chloro-5,6-benzo-1,3,2-dioxaphosphorin-4-one (2) and solid-liquid extraction with CH2Cl2 / hexane (1: 1) to yield the 5'-DMT-3'-H-phosphonate of 4.
[159] For a solution of 1 (3.94 g, 5 mmol) in 15 ml of anhydrous dioxane and 5 ml of dry pyridine, 5.6 ml (7.0 mmol) of a stock solution of 1 was added with stirring , 25 M in 2-crying-5,6-benzo-1,3,2-dioxaphosphorin-4-one dioxane (2). After 15 min, the reaction was quenched with 1 ml of water and the mixture poured into 10 ml 0.25 M NaHCO3, followed by extraction (3x15 ml) with ethyl acetate. The organic phase was dried (Na2SO4) and concentrated to yield 3.8 g. The solid was triturated with 100 ml of CH2Cl2 / hexane (1: 1), filtered, and the residual solid dried to yield a fine white powder (3.5 g) which functioned as a TLC site (Rf = 0.1) eluting with 5% CH3OH in CH2Cl2 with 0.5% triethylamine.
[160] b) Destrituration by sodium bisulfate absorbed on silica gel (NaHSO4-SiO2) and precipitation of 5'-OH-3'-H-phosphonate (5).
[161] To a solution of 4 (1.74 g, 2 mmol) in 85 ml of dichloromethane and 0.072 ml of water (4 mmol) 0.55 g of NaHSO4-SiO2 (2.4 mmol H + / gr NaHSO4) were added -SiO2). The reaction was complete after stirring at room temperature for 35 minutes (TLC in 10% MeOH in CH2 Cl2 with 0.5% TEA). NaHSO4-SiO2 was removed by filtration and washed (3 x 5 ml) with CH2 Cl2. 100 ml of hexane: toluene (1: 1) were added, vortexed for 5 minutes and the solvent was decanted (repeated twice). Evaporation gave 0.92 g of 5 as a solid. Analytical HPLC indicated 96.4% purity. LC / MS in negative mode confirmed m / z (M-1) 548.2 (calculated for C23H3iN5O7PSr: 548.2).
[162] c) Coupling, oxidation and destruction.
[163] DMT-rA (bz) -pCE-TBDMS-phosphoramidite (3) (3.5 g, 3.6 mmole) was co-evaporated three times with 20 ml of dry acetonitrile, the last time leaving about 10 ml in volume , to which 10 molecular sieves 3A were added. The solution was left under dry argon.
[164] 1.6 g of H-phosphonate (5) was evaporated three times from anhydrous CH3CN, the last time leaving 100 ml. This solution was added to the dry phosphoramidite solution via syringe, followed by 1.4 g of pyridinium trifluoroacetate (which had been dried by evaporation of 3x20 ml of anhydrous pyridine). After 20 min 3 ml of 5.5 M tert-butyl hydroperoxide were added and stirred for 30 min. After cooling in an ice bath, 0.3 g of NaHSO3 in 1 ml of water were added and the mixture stirred for 5 min. The solvent was then evaporated and the residue was taken up in 20 ml (CH2 Cl2 / MeOH, 98: 2). The sieves were filtered out and the solvent changed to 81 ml of CH2 Cl2. NaHSO4-SiO2 (513 mg) and water (65 microliters) were added and the reaction stirred for 40 min. The mixture was filtered through Celite, the pad washed with CH2 Cl2 and the filtrate evaporated to yield crude 7a. LC / MS in negative mode confirmed m / z (M-1) 1148.5 (calculated for C ^ F ^ NnO ^ Si /: 1148.37.
[165] d) Cycling of linear dimer (7a) and oxidation to yield 8a.
[166] To the 7th product (dried by evaporating anhydrous pyridine leaving 100 ml after final evaporation) DMOCP (1.9 g, 10.15 mmol) was added. After 12 minutes, the reaction was quenched with water (2.3 g), followed immediately by the addition of iodine (0.96 g, 3.78 mmol). The reaction mixture was poured into 400 ml of water containing 0.6 g NaHSO3. After 5 min of stirring, 11.2 g of NaHCO3 were added in portions and the solution stirred for 5 min. The mixture was partitioned twice with 500 ml of ethyl acetate / ether (3: 2). The organic layers were combined, dried (Na2SO4) and evaporated. Toluene (3 x 10 ml) was added and evaporated to remove residual pyridine to yield 2.37 g of 8a as a yellow-brown solid. LC / MS in negative mode confirmed m / z (M-1) 1146.6 (calculated for 1146.4
[167] e) Deprotection of crude 8a with concentrated ammonium hydroxide to yield crude 9a and prepare HPLC to yield 9a in pure form.
[168] To 600 mg of 8a in a 200 ml thick-walled pressure tube 40 ml of methanol and 40 ml of aqueous ammonia concentrate were added, and the resulting mixture was stirred at 50 ° C for 16 hr. The reaction mixture was concentrated in vacuo and the residue washed with ethyl acetate (3x10 ml) to yield 510 mg of 9a crude.
[169] The 102 mg portion of 9a crude in 4 ml of 20% CH3CN in 10 mm triethylammonium acetate was applied to the prep HPLC column and eluted using an acetonitrile gradient and 10 mM triethylammonium acetate in water (20- > 50% CH3CN, more than 20 minutes in the flow of 50 ml / min). HPLC fractions containing pure 9a were pooled, evaporated to remove CH3CN and lyophilized to remove remaining water and volatile buffer to give 32 mg of pure 9a as the bis-triethylammonium salt. LC / MS in negative mode confirmed m / z (M-1) 885.5 (calculated for C32Hs1N10O12P2Si2 ': 885.3. (It was also possible to postpone the HPLC prep purification until after the last step, as described in the c-di-GMP series and dithio-c-di-GMP below).
[170] f) Deprotection of 9a TBS groups with triethylamine fluoride, neutralization with TEAB and extraction of solid phase with a C18 Sep-Pak to yield pure 10a as the bis-triethylammonium salt.
[171] To 20 mg of 9a 0.25 ml of triethylamine trihydrofluoride was added. The mixture was placed on a shaker for 48 hours at which point an analytical HPLC of a 10 microliter sample neutralized with 100 microliters of 1M triethylammonium bicarbonate indicated the consumption of raw material and the appearance of a single new product. The reaction mixture was then added dropwise by stirring to a 10 x volume of chilled 1 M triethylammonium bicarbonate. The neutralized solution was then loaded onto a Waters C-18 Sep-Pak, and after washing the column with 6 volumes of 10 mM triethylammonium acetate, the product was eluted with CH3CN: triethylammonium acetate (1: 1). CH3CN was removed by rotoevaporation and the aqueous sample was lyophilized to dryness to yield 14 mg of 10a as the bis-triethylammonium salt. HRMS 10a in negative mode confirms m / z (M-H) 657.0985 (calculated for C2oH23N10012P2 '• 657.0978). 1H NMR (D2O) 45 ° C õ (ppm) 8.34 (s, 2H), 8.11 (s, 2H), 6.15 (s, 2H), 4.34 (m, 4H), 4.15 (m, 2H), 3.77 (m , 2H), 3.19 (q, J = 7Hz), 1.27 (t, J = 7Hz). 31P NMR (D2O) 25 ° C. δ (ppm) -1.74.
[172] Example 3. Synthesis of 10b and 10c.
[173] The following synthesis is described schematically in Fig 6.
[174] a) Hydrolysis of commercially available DMT-rA DMT-rA (bz) - pCE-TBDMS-phosphoramidite (3), p-elimination and silica chromatography of the resulting 5'-DMT-3'-H-phosphonate (4 ):
[175] To a solution of DMT-rA (bz) -pCE-TBDMS-phosphoramidite (3) (11 g, 11.1 mmol) in 50 ml of acetonitrile, water (0.36 ml, 20 mmol, 1.8 equiv) was added and pyridinium trifluoroacetate (2.3 g, 11.9 mmol, 1.07 equiv). After stirring the mixture for 5 minutes at room temperature, tert-Butylamine (50 ml) was added and stirring was continued for another 10 minutes. The mixture was then concentrated to a foam which was taken up in dichloromethane and applied to a column of silica gel eluting with a gradient of 5% to 10% MeOH in dichloromethane. Column fractions containing the desired product were pooled and concentrated to yield 5'-DMT-3'-H-phosphonate (4) as a foam (6.68 g, 7.8 mmol, 70% yield)
[176] b) Destrituration and precipitation of 5'-OH-3'-H-phosphonate (5):
[177] To a solution of 4 (6.68 g, 7.8 mmol) in 60 ml of dichloromethane and 1.4 ml of water (78 mmol, 10 equiv) was added a 100 ml portion of 6% dichloroacetic acid in dichloromethane (73 mmol, equiv 9.35). After stirring at room temperature for 10 minutes, pyridine (11.2 ml, 139 mmole, 1.9 equiv based on DCA) was added to quench the acid and the concentrated mixture to yield 5 as a yellow / orange glass. The glass was taken up in about 20 ml of dichloromethane and added dropwise with stirring to 500 ml of 7: 3 hexane: diethyl ether to precipitate out the desired 5'-OH-3'-H-phosphonate (5). The supernatant was decanted away from the precipitate (most of which formed a gum attached to the walls of the flask) and was dried under reduced pressure to form a granular slurry. This slurry was evaporated three times with 40 ml of dry acetonitrile, the last time leaving about 12 ml.
[178] c) Preparation of a dry solution of phosphoramidite (3), in acetonitrile, coupling with 5'-OH-3'-H-phosphonate 5) and sulfurization for linear dimer thiophosphate (6b) and destructuration to 7b.
[179] DMT-rA (bz) -pCE-TBDMS-phosphoramidite (3) (9.08 g, 9.36 mmol, 1.2 equiv based on H-phosphonate (5) was co-evaporated three times with 40 ml of dry acetonitrile, the last instead leaving about 20 ml of volume, to which 10 molecular sieves 3A were added.The solution was left under dry argon.
[180] To the phosphoramidite solution (3) 5 (from b) was added with stirring under dry argon. After stirring for 10 minutes at room temperature, half of the reaction mixture (for conversion to dithio analogs) was transferred under argon to a second reaction vessel and 3 - (((N, N-dimethylaminomethylidene)) amino-3H-1, 2,4-dithiazol-5-thione (0.88 g, 4.29 mmol, equivalent 1.1) was added in. After 30 min stirring at room temperature, the reaction was stopped by placing it in a -20 ° C freezer. When stored in a freezer for> 48 h a yellow precipitate separated from the solution, the mixture was filtered and the filtrate concentrated in a foam (3.9 g), dissolved in 50 ml of CH2 Cl2 and treated with 100 ul of water followed immediately per 800 mg of NaHSO4-silica The mixture was stirred for 30 min at room temperature and filtered to remove the silica.60 ml of hexane was then added to the filtrate and an oiled lower phase out of the solution.The oil was separated and evaporated to yield 3.1 g of crude 7b.
[181] d) Cycling of linear dimer (7b), sulfurization and silica chromatography to give a mixture of 8b and 8ç.
[182] 7b (3.05 g, 2.6 mmol) was dried by evaporation from anhydrous pyridine (200 ml of pyridine was added and rotoevaporated leaving 120ml) followed by the addition of DMOCP (1.68 g, 9.1 mmol, 3.5 equiv). After 12 minutes, the reaction was quenched with water (1.63 g, 91 mmol), followed immediately by the addition of 0.675 g (3.0 mmol, 1.2 equiv) of 3-H-1,2-benzodithiol-3-one. The reaction mixture was poured into 500 ml of 0.25 M sodium bicarbonate and then extracted 2 x 500 ml with ethyl acetate / diethyl ether (3: 2). The organic layers were combined, dried (Na2SO4) and evaporated in vacuo. Toluene (3 x 10 ml) was added and evaporated to remove residual pyridine. The residue was applied to a silica column and eluted with a 0 to 10% gradient of CH30H in CH2 Cl2 to give a total of 1.47 g containing mainly diastereoisomers 8b and 8c.
[183] e) Deprotection of the mixture of 8b and 8c with concentrated ammonium hydroxide to give 9b and 9c, and separation via HPLC prep to give 9b and 9c in pure form.
[184] To 230 mg of a mixture of 8b and 8c in a glass pressure tube, 16 ml of methanol was added followed by 16 ml of aqueous ammonia concentrate, and the resulting mixture was stirred at 50 ° C for 16 hr. The reaction mixture was concentrated in vacuo and the residue washed with ethyl acetate (3x10 ml) to yield 210 mg of 9b and 9ç crude mixture. LC / MS in negative mode for mixture 9b / 9c confirmed m / z (M-1) 917 (calculated for C32H51N10O10P2S2SÍ2 ': 917.2.
[185] Separation of the 9b / 9c mixture via prep HPLC. A 105 mg portion of crude mixture 9b and 9c in 4 ml of 30% CH3CN in 10 mM triethylammonium acetate was applied to the prep HPLC column and eluted using an acetonitrile gradient and 10 mM triethylammonium acetate (30-> 50 % CH3CN, more than 20 minutes in the flow of 50 ml / min). HPLC fractions containing pure 9b were separated from those containing pure 9ç. The pooled fractions were evaporated to remove CH3CN and lyophilized to remove remaining water and volatile buffer to give 18 mg of 9b and 14 mg of 9c as the bis-triethylammonium salts.
[186] f) Deprotection of 9b TBS groups with triethylamine trihydrate fluoride, TEAB neutralization and solid phase extraction (SPE) with a C-18 Sep-Pak to yield pure 10b as the bis-triethylammonium salt.
[187] To 8 mg of 9a 0.4 ml of triethylamine trihydrofluoride was added. The mixture was placed on a shaker for 16h at which point an analytical HPLC of a 5 microliter sample neutralized with 100 microliters of 1M triethylammonium bicarbonate (TEAB) indicated the consumption of raw material and the appearance of a single new product. The reaction mixture was then added dropwise by stirring to a volume of -10 x of chilled 1 M triethylammonium bicarbonate. The neutralized solution was then loaded onto a Waters C-18 Sep-Pak, and after washing the column with 6 volumes of 10 mM triethylammonium acetate, the product was eluted with CH3CN: 10mm triethylammonium acetate (1: 5). CH3CN was removed by rotoevaporation and the aqueous sample was lyophilized to dryness to yield 6 mg of 10b as the bis-triethylammonium salt. HRMS of 10b in negative mode confirms m / z (M-H) 689.0526 (calculated for C20H23N1001OP2S2 ': 689.0521). 1H NMR (D2O) 35 ° C Õ8.39 (s, 2H), Õ8.16 (s, 2H), Ô6.16 (s, 2H), õ4.97-5.03 (m, 2H), Õ4.78 ( m, 2H), Õ4.50-4.55 (m, 4H), 04.04-4.08 (m, 2H), Õ3.20 (q, j = 7Hz), Õ1.27 (t, J = 7Hz). 31PNMR (D2O) 25 ° C. (Ppm) 54.41.
[188] g) Deprotection of 9c TBS groups with triethylamine trihydrofluoride, neutralization with TEAS and solid phase extraction with a C18 Sep-Pak to yield 10c pure as the bis-triethylammonium salt.
[189] To 6 mg of 9c, 0.3 ml of triethylamine trihydrofluoride was added. The mixture was placed on a 16 h stirrer and a small aliquot procedure as in (f) indicated consumption of raw material and the appearance of a single new product. The reaction mixture was then added dropwise by stirring to a volume of ~ 10 x of chilled 1 M triethylammonium bicarbonate. The neutralized solution was then loaded onto a Waters C-18 Sep-Pak, and after washing the column with 6 volumes of 10 mM triethylammonium acetate, the product was eluted with CH3CN: 10mm triethylammonium acetate (1: 5). CH3CN was removed by rotoevaporation and the aqueous sample was lyophilized to dryness to yield 4 mg of 10c as the bis-triethylammonium salt. HRMS of 10b in negative mode confirms m / z (M-H) 689.0524 (calculated for C2oH23N10010P2S2 ': 689.0521). 1H NMR (D2O) 35 ° C õ (ppm) 8.50 (s, 2H), Õ8.37 (s, 2H), Õ8.20 (s, 2H), Õ8.10 (s, 2H), Õ6.17 ( s, 2H), Õ6.14 (s, 2H), õ5.06-5.07 (m, 2H), 54.96-5.02 (m, 2H), Õ4.87-4.93 (m, 2H), Õ4.75 (m , 2H), Õ4.34-4.56 (m, 10H), õ3.98-4.13 (m, 2H), Õ3.20 (q, J = 7Hz), Õ1.27 (t, J = 7Hz). 31PNMR (D2O) 25 ° c. õ (ppm) 54.54, 54.84, 55.92 (smaller).
[190] Example 4. Synthesis of (11a), (11b) and (11c).
[191] 11a, 11b and 11c were synthesized, as described in Gaffney et al. with the addition of HPLC prep purification of the final product (exemplified below) instead of recrystallization, in order to achieve purities of> 97% for biological tests. Alternatively, HPLC prep purification can be performed after the cyclization and deprotection steps as described for the adenosine series in Fig. 6, examples 2 and 3.
[192] 11a
[193] The 100 mg portion of 11a in 3 ml 10mm triethylammonium acetate was applied to the prep HPLC column and eluted using an acetonitrile gradient and 10 mM triethylammonium acetate in water (0% to 10% CH3CN gradient for more than 22 minutes in the 50 ml / min flow). HPLC fractions containing pure 11a were pooled and the CH3CN was removed by rotoevaporation and the remaining aqueous sample lyophilized for drying to yield 40mg of pure 11a as the bis-triethylammonium salt. 11a HRMS in negative mode as m / z (M-H) 689.0893 (calculated for C2oH23N10014P2 ': 689.0876). 1H NMR (D2O) 45 ° C δ (ppm) 8.05 (s, 2H), 5.98 (s, 2H), 4.90 (m, 2H), 4.76 (m, 2H), 4.41 (m, 2H), 4.33 (m , 2H), 4.09 (m, 2H), 3.19 (q, J = 7Hz, 6H), 1.28 (t, J = 7Hz, 9H). 31PNMR (D2O) 25 ° C. δ (ppm) -1.24.
[194] 11b
[195] The 100 mg portion of 11b enriched in 3 ml 6% CH3CN in 10 mm triethylammonium acetate was applied to the prep HPLC column and eluted using an acetonitrile gradient and 10 mM triethylammonium acetate in water (6% a 18% CH3CN gradient for more than 22 minutes at 50 ml / min flow). HPLC fractions containing pure 11b were pooled and the CH3CN was removed by rotoevaporation and the remaining aqueous sample lyophilized for drying to yield 40mg (40% yields) of pure 11b as the bis-triethylammonium salt. 11b HRMS in negative mode confirmed m / z (M-H) 721.0446 (calculated for C20H23N10O12P2S2 ': 721.0419). 1H NMR (D2O) 45 ° C Õ 8.05 (s, 2H), 5.98 (s, 2H), 5.03 (m, 2H), 4.77 (m, 4H), 4.10 (m, 2H), 4.08 (m, 2H) , 3.19 (q, j = 7Hz, 6H), 1.28 (t, J = 7Hz, 9H). 31PNMR (D2O) 25 ° C. 54.87.
[196] 11c
[197] The 60 mg portion of 11 enriched in 3 ml 6% CH3CN in 10 mm triethylammonium acetate was applied to the prep HPLC column and eluted using an acetonitrile gradient and 10 mM triethylammonium acetate in water (6% to 18% % gradient of CH3CN for more than 22 minutes in the flow of 50 ml / min). HPLC fractions containing the pure 11c were pooled and the CH3CN was removed by rotoevaporation and the remaining aqueous sample lyophilized for drying to yield 30mg (50% yield) of pure 11c as the bis-triethylammonium salt. 11c HRMS in negative mode confirmed m / z (M-2H) 360.0171 (calculated for C2OH22NW012P2S2'2: 360.0173). 1H NMR (D2O) 55 ° C δ (ppm) 8.13 (s, 2H), 8.03 (s, 2H), 5.97 (m, 2H), 5.06-5.12 (br, 4H), 4.98-5.00 (m, 2H) , 4.81-4.83 (m, 2H), 4.04-4.08 (m, 4H), 3.20 (q, j = 7Hz), 1.27 (t, J = 7Hz). 31PNMR (D2O) 25 ° C. (Ppm) 54.77, 56.00.
[198] Example 5: Induction of interferon by CDNs
[199] To determine the relative level of 1FN-0 in antigen presenting cells induced by each of the Rp, Rp dithio c-di-GMP molecules relative to the unmodified GMP-di-c molecules as a signature of adjuvant potency, 1x105 DC2.4 cells, a H-2b-restricted mouse dendritic cell line derived from the mouse, were incubated with 5, 20 and 100 pM c-di-GMP, Rp, Rp and Rp, or Sp dithio -diphosphate c-di-GMP, as well as dithio diphosphate c-di-AMP molecules Rp, Sp or c-di-AMP Rp, Rp or HBSS for 30 minutes at 37 ° C with 5% CO2. After 30 minutes, the cells were washed and replaced with RPMI media containing 10% FBS. To measure the level of induced IFN-P, cell culture fluids from each sample were collected after 4 hours, and 10 µl were added to 5x104 L929-ISRE luciferase reporter cells cultured in RPMI + 10% FBS media. The relative level of IFN-0 production was determined by measuring relative light units (RLU) after 4 hours of incubation,
[200] As shown in Fig. 7, the Rp, Rp dithio c-di-GMP diastereoisomers and Rp, Rp dithio c-di-AMP induced significantly higher levels of IFN-p than both unmodified cyclic dinucleotide molecules of c-di-GMP or c-di-AMP. In addition, the IFN-p level induced by the Rp, Sp dithio c-di-GMP and Rp diastereoisomers, Sp dithio c-di-AMP was lower than the level induced by both Rp, Rp dithio c-di-GMP diastereoisomers and Rp, Rp dithio c-di-AMP as well as the native GMP-di-c and c-di-AMP molecules. These results demonstrate that purified preparations of Rp, Rp dithio c-di-GMP and Rp, Rp dithio c-di-AMP diastereoisomers more deeply activate the innate immune response than the GMP-di-c and c-di-AMP molecules without modifications, as well as the derivatives of Rp, Sp dithio. The thio-derivatives Rp, Sp derived from c-di-GMP and c-di-AMP poorly activated the innate immune response. It will be evident to those skilled in the art that preferred modalities of adjuvants are cyclic dinucleotides Rp, Rp dithio diphosphate c-di-GMP or Rp, Rp dithio diphosphate c-di-AMP, due to their properties of greater activation of the innate immune response , as shown by the magnitude of the induced IFN-p expression, compared to any Rp, Sp c-di-GMP dithio diphosphate or Rp, C-di-AMP dithio diphosphate or c-di-GMP or c- di-AMP.
[201] Example 6. Degradation of CDNs by phosphodiesterases
[202] A mechanism for the greater potency of derivatives of Rp, Rp dithio diphosphate c-di-GMP and c-di-AMP compared to native unmodified c-di-GMP and c-di-AMP may be the resistance of dithio-modified derivatives to host cell phosphodiesterase degradation. As a test for this mechanism, Rp, Rp dithio c-di-GMP, unmodified c-di-GMP and also Rp molecules, Rp dithio c-di-AMP and c-di-AMP were incubated with and without 1 mg of snake venom phosphodiesterase (SVPD) overnight at 37 ° C. After this incubation period, SVPD enzyme in the reactions was inactivated and removed by incubation at 100 ° C for 10 minutes and the samples were then centrifuged at 14,000 rpm for 5 minutes. To test the relative ability of the samples to activate innate immunity, measured by the level of IFN-p expression, 1x105 DC2.4 cells were incubated with 100 pM derivatives of Rp, Rp dithio diphosphate c-di-GMP and c- di-AMP and c-di-GMP and native unmodified c-processed from samples incubated with these cyclic dinucleotide preparations for 30 minutes at 37 ° C with 5% CO2. After 30 minutes, the cells were washed and replaced with RPMI media containing 10% FBS and incubated for an additional 4 hours. The culture fluids were then harvested, and 10 µl of those fluids were added to 5 x 104 L929-ISRE luciferase reporter cells cultured in RPMI media containing 10% FBS. The relative level of IFN-p expression was determined by measuring relative light units (RLU) after 4 hours of incubation in the reporter cell line.
[203] As shown in Fig. 8, the level of IFN-p expression in cells containing Rp, Rp dithio diphosphate c-di-GMP ("RR-CDG") or Rp, Rp dithio diphosphate c-di- AMP ("RR-CDA") was equivalent, regardless of whether the cyclic dinucleotides were incubated with SVPD. In contrast, the level of IFN-p expression was significantly lower in cultures containing c-di-GMP ("CDG") or c-di-AMP ("CDA") that had previously been incubated with SVPD, compared to cultures containing c-di-GMP or c-di-AMP that had not been incubated with this enzyme. In addition, in cultures containing cyclic dinucleotides not incubated with SVPD, the level of IFN-p expression was higher with Rp, Rp dithio-diphosphate c-di-GMP or Rp, Rp dithio-diphosphate c-di-AMP compared to c-di-GMP or c-di-AMP. These data further support the idea of the greater potency of Rp, Rp dithio-diphosphate c-di-GMP or Rp, Rp dithio-diphosphate c-di-AMP compared to c-di-GMP or c-di-AMP.
[204] Example 7. Induction of the immune response by CDNs
[205] To test the enhanced in vivo immunogenicity of Rp, Rp dithio c-di-GMP against unmodified GMP-di-c molecules, CD4 + and CD8 + OVA-specific T cell responses were measured in PBMCs in 10 days post vaccination in conjunction with CDN treatment. The vaccines were prepared by combining 10 pg of OVA protein (EndoFit OVA, InVivogen) and Addavax (2% final squalene) with 25 pg or 5 pg of cyclic dinucleotide, in a total volume of 100 pl. Groups of five female C57BL / 6 (H-2b) mice were immunized once subcutaneously (SC) at the base of the tail with vaccine preparations and CD4 + and CD8 + T OVA-specific T cell responses in the blood compartment peripheral mononuclear cell (PBMC) were determined by ELISpot analysis 10 days later. 1x105 PBMCs and 1x105 splenocyte feeder cells isolated from naive age-matched C57BL / 6 mice were stimulated or unstimulated with 1 pM MHC class II peptide (TEWTSSNVMEERKIKV OVA265- 280) or MHC class I peptide (OVA257-264 SIINFEKL) overnight and cells that form IFN-γ mark were measured, as previously described.
[206] As shown in Fig. 9, CD4 + and CD8 + OVA-specific T cell responses were of greater magnitude in mice immunized with vaccines containing Rp, Rp dithio c-di-GMP compared to unmodified c-di-GMP, in formulations containing the same amount of the adjuvant cyclic dinucleotide. In addition, the magnitude of CD8 + antigen-specific T cell responses were greater in mice immunized with vaccine formulations containing 5 pg of Rp, Rp dithio c-di-GMP, compared to mice immunized with vaccine formulations containing 5 pg or 25 pg of unmodified c-di-GMP.
[207] Example 8. Induction of T cell response by CDNs
[208] To assess the immunogenicity of Rp, Rp dithio c-di-GMP against unmodified GMP-di-c molecules, CD8 + and CD4 + gag-specific SIV cell responses were measured. Five C57BL / 6 mice per group were immunized subcutaneously twice with 1 µg of Rp, Rp dithio c-di-GMP or saline control formulated in 2% squalene-in-water with 10 µg of SIV gag protein. The vaccines were separated for 20 days, and spleens were collected six days after the second vaccination. Immune responses were measured for CD8 (AL11, SIV gag312-322. A) and CD4 (DD13, SIV gag3oo-3i2> 8) gag-specific SIV epitopes by IFNy ELISpot assay. The plates were scanned and spot-forming cells (SFC) per well were enumerated using an ImmunoSpot (CTL) analyzer.
[209] As shown in Fig. 10, animals immunized with RR c-di-GMP induced significantly higher CD8 and CD4 gag-specific SIV responses compared to animals that received saline control. These results demonstrate that vaccine formulations with the c-di-GMP RR derivative can induce SAG gag-specific CD4 and CD8 T cell responses in vivo. Those skilled in the art will recognize that vaccine formulations containing Rp, Rp c-di-GMP dithiophosphate or Rp, Rp c-di-AMP dithiophosphate are preferred, as such cyclic dinucleotides have greater potency as shown by the greater magnitude of immune responses induced by vaccine, and also the greater magnitude of vaccine-induced immune responses with comparatively lower levels of adjuvant dose.
[210] Example 9. Induction of protective immunity by CDNs
[211] To establish the enhanced immunogenicity and accompanying protective immunity induced by Rp, Rp dithio c-di-GMP in relation to unmodified c-di-GMP, OVA-specific CD8 T cell responses measured in PBMC and protective immunity assessed against lethal bacterial challenge. The vaccines were prepared by combining 10 pg of OVA protein (EndoFit OVA, InVivogen) and Addavax (2% final squalene) with 25 pg or 5 pg of cyclic dinucleotide, in a total volume of 100 pl. Groups of five female C57BL / 6 mice (H-2b) were immunized twice subcutaneously (SC) at the base of the tail with vaccine preparations. The interval between initiation and increment immunizations was 36 days. The magnitudes of the memory and expansion phases of CD8 OVA257-specific T cell responses in PBMC were quantified by intracellular cytokine staining (ICS) analysis at 27 days post-increment vaccination and 3 days after challenge with a lethal dose 2X (LD) 50 (colony-forming units 1 x 105; CFU) of wild type Listeria monocytogenes that express OVA (WT Lm-OVA). For ICS analysis, 1 x 105 PBMCs from test mice combined with 1 x 105 splenocyte feeder cells isolated from naive C57BL / 6 age-matched mice were stimulated or not stimulated with 1 pM MHC class I peptide (OVA257-264 SIINFEKL) for 5 hours in the presence of Brefeldin A and IFN-y production was measured by flow cytometry in a BD FACSVerse.
[212] As shown in Fig. 11A, mice immunized with Rp, Rp dithio diphosphate c-di-GMP vaccines generated a greater magnitude of OVA-specific CD8 T memory cells compared to mice immunized with vaccines adjuvanted with unmodified c-di-GMP. OVA-specific memory CD8 T cells induced by immunization with Rp, Rp dithio-diphosphate c-di-GMP adjuvanted expanded vaccines to a greater extent after challenge with the pathogen expressing the cognate OVA antigen, compared to the level of expansion of OVA-specific CD8 T memory cells in mice immunized with c-di-GMP adjuvanted vaccines without modification. The graphical representation of FACS shown in Fig. 11B demonstrates that the magnitude of CD8 OVA-specific T memory cells approached 30% of the total CD8 T cell population in PBMC of mice immunized with Rp, Rp dithio diphosphate c-di -GMP with adjuvanted vaccines. The gold standard for effective immunization is to test whether a vaccine candidate can provide protection against subsequent challenge with a virulent pathogen. To test the relative efficacy of Rp, Rp dithio c-di-GMP and c-di-GMP adjuvanted vaccines without modification, mice were challenged with intravenous injection of 2X dose LD50 (1 x 105 CFU) of wild-type Listeria monocytogenes Expressive OVA (WT Lm-OVA) 27 days after the increment immunization. Three days later, protective immunity was determined by plating homogenate dilutions from spleens harvested from test mice 3 days post challenge of WT Lm-OVA on brain-heart infusion agar media, and quantifying the number of colonies after incubation overnight at 37 ° C. Fig. 11C shows the immunization of mice with Rp, Rp dithio diphosphate c-di-GMP with adjuvanted vaccines offered complete protection (below the detection limit, LOD) against the challenge of virulent pathogen. It will be evident to those skilled in the art that preferred modalities of adjuvants are cyclic Rp, Rp dithio diphosphate c-di-GMP or Rp, Rp dithio diphosphate c-di-AMP, due to their properties of conferring deep vaccine potency, as shown by high-magnitude CD8 T cell memory cluster induction that expands when it is challenged with the cognate antigen and provides complete protection against the virulent pathogen challenge.
[213] Example 10. Induction of effective anti-tumor immunity by CDNs
[214] The relative antitumor efficacy of in vivo derivatives of Rp, Rp dithio c-di-AMP and c-di-AMP without modification was evaluated in a mouse model of subcutaneous prostate cancer. The derived molecules were formulated with 1 x 106 murine TRAMP-C2 prostate tumor cells completely irradiated expressing GM-CSF (GVAX). Groups of 5 male C57BL / 6 mice were implanted with 1 x 105 subcutaneous TRAMP-C2 tumor cells in the paw pad. On days 4 and 11 after tumor implantation, mice were given subcutaneous vaccines on the flank of GVAX alone or GVAX formulated with RR-CDA or CDA and in relation to the HBSS control. Tumor growth was monitored by forceps, and tumor volume was calculated.
[215] [00202] As shown in Fig. 12, by day 52 post tumor implantation, mice vaccinated with GVAX + RR-CDA demonstrated significant inhibition of tumor growth compared to the HBSS control, with greater antitumor effectiveness compared to GVAX alone or GVAX formulated with c-di-AMP derivative without modification. These data demonstrate the increased antitumor potency of the Rp-derived molecule, Rp dithio AMP-di-c compared to the unmodified c-di-AMP molecule in a murine model of prostate cancer.
[216] Example 11. Produce forms of CDNs.
[217] Pro-drug strategies provide an attractive method to facilitate partitioning in the bilayer of delivery cells or liposomes. Acylation of the 2'-OH ribose from GMP-di-c, c-di-AMP and dithio-analogs with C-12 to C-18 carboxylic acids could serve as a valuable prodrug. Two examples are shown in Fig. 13 and described in the example. [00204] (a) Synthesis of mono-2'-O-myristoyl c-di-GMP 12 of 11a.
[218] For the 11a bistriethylamine salt (8 mg, 9.0 micromoles) 0.3 ml DMF, 30 microliters of pyridine and 15 mg of myristic anhydride (34 micromoles) were added. The reaction mixture was stirred at room temperature for 48 hours and then heated to 60 ° C for 0.5 hours. The mass of main product 12 was confirmed by LC / MS in negative mode, with m / z (M-1) 889 (calculated for C34H49N10O15p2-: 899.3). After evaporation, the residue was taken up to 30% CH3CN in 10mm TEAA, filtered and purified on a 20mm prep C-18 HPLC column with gradient elution (30 to 60% CH3CN in 10mm TEAA for another 20 min in a flow of 20 ml / min). Fractions containing the desired product were combined, rotoevaporated and lyophilized to give 3 mg of mono-2'-O-myristoyl c-di-GMP (12). HRMS of 12 in negative mode confirms m / z (M-2) 449.1389 (calculated for C34H48N1015oP2'2: 449.1393). 1H NMR (DMSO + 1% D2O) 25 ° C δ (ppm) 7.98 (s, 2H), 5.98 (s, 1H), 5.73 (d, 1H), 5.66 (s, 1 H), 4.74 (d, 2H ), 4.54 (s, 1H), 4.23 (s, 1H), 3.81-3.99 (br, 4H), 2.55 (s, 2H), 1.44 (s, 2H), 0.85 (t, 3H). (NMR peaks at 10.61, 7.33 and 6.55 in pure DMSO were exchanged in the addition of 1% D2O). Methylene from the miristoil group were obscured by field triethylammonium acetate and DMSO peaks. NMR is consistent with monoacylation on 2'-OH. 31P NMR (D2O) 25 ° C. δ (ppm) -1.37, -2.06.
[219] (b) Synthesis of mono-2'-O-myristoyl dialkyl [Rp, Rp] 11b c-di-GMP dithiophosphate (13).
[220] For the 11b bistriethylamine salt (12 mg, 13.0 micromoles) 0.3 ml DMF, 30 microliters of pyridine and 15 mg of myristic anhydride (34 micromoles) and catalytic DMAP were added. The reaction mixture was stirred at room temperature for 24 hours and then heated to 60 ° C for 2 hours. The solvent was removed by rotoevaporation and the residue taken up in 50% MeOH in 10mm TEAA, filtered and purified on a 20mm C-18 HPLC column prep (50% MeOH in 10mm isocratic TEAA for 5 min followed by gradient to 100% MeOH for 10 min and then 100% MeOH for 10 min). The desired product eluted late in this methanolic system. The fractions containing the desired product were combined, rotoevaporated and then lyophilized to give 4 mg of mono-2'-O-myristoyl [Rp, Rp] c-di-GMP dithiophosphate (13). HRMS of 13 in negative mode confirms m / z (M-2) 465.1148 (calculated for C34H48N10O13P2S2'2: 465.1165). 1H NMR (DMSO + 1% D2O) 25 ° C δ (ppm) 8.01 (s, 2H), 5.97 (d, 1H), 5.73 (d, 2H), 5.71 (m, 2H), 5.00 (m, 1H) , 4.85 (m, 1H), 4.56 (m, 1H), 4.10-4.18 (m, 4H), 3.97 (m, 2H), 3.84-3.87 (m, 1H), 3.16 (s, 1H), 3.05 (d , 2H), 1.47 (br, 2H), 0.85 (t, 3H). (NMR peaks at 10.60, 7.53, 6.90 and 6.63 in pure DMSO were exchanged in addition of 1% D2O). Methylene from the miristoil group were obscured by field triethylammonium acetate and DMSO peaks. NMR is consistent with monoacylation on 2'-OH. 31P NMR (CD3OD) 25 ° C. (Ppm) 56.66, 55.46.
[221] A similar pro-drug approach using sulfur acyloxyalkyl or oxygen derivatization in thiophosphates and CDN phosphates, respectively, can also be used. The acyloxyalkyl structures in Fig. 14 are similar to Adefovir, an effective pro-drug analog nucleoside that is used to treat HIV and HBV infection. Once inside the cell, intracellular esterases will cleave the acyl or acyloxyalog groups present in 2'-OH or phosphate (thiophosphate) and regenerate the subderivated cyclic dinucleotide.
[222] Example 12. Pharmacological activity of CDN prodrugs.
[223] To determine the relative potency of the pro-drug form of c-di-GMP to activate the innate immune response, relative levels of IFN-p induced in a human monocyte cell line were evaluated. For these experiments, 4 x 105 human THP1-Blue monocytes were transfected with an IRF-inducible secreted embryonic alkaline phosphatase reporter gene (Invivogen) and incubated with 100 µM c-di-GMP, mono-2'-O-myristoyl c -di-GMP or HBSS for 30 minutes at 37 ° C with 5% CO2. After 30 minutes, the cells were washed and plated in a 96-well plate in RPMI media containing 10% FBS and incubated at 37 ° C with 5% CO2. Cell culture supernatants from each sample were collected after 4 hours. 10 µl of the cell culture supernatants were added to the QUANTI-Blue reagent (Invivogen) and incubated for 1530 minutes. Absorbance at 655 nm was measured using a model 680 spectrophotometer (BioRad).
[224] As shown in Fig. 15, the mono-2'-O-myristoyl c-di-GMP derivative ("mono-2'-O-myristoyl CDG") induced significantly higher levels of IFN-p on the c-di-GMP cyclic dinucleotide molecule without modifications and on background levels (HBSS) in a human monocyte cell line. In addition, these data demonstrate in a human monocyte cell line the superior induction of Rp, Rp dithio c-di-GMP molecules over Rp, Sp dithio c-di-GMP and GMP-di-c molecules modified. These results demonstrate that purified preparations of mono-2'-O-myristoyl c-di-GMP derivatives can activate the innate immune response in a human cell line.
[225] Example 13. Induction of immune responses by CDN prodrugs
[226] To assess the ability of the mono-2'-O-myristoyl c-di-GMP derivative ("mono-2'-O-myristoyl CDG") to induce immune responses in vivo, CD8 OVA- Specific measures were measured in splenocytes 7 after the second vaccination in conjunction with CDN treatment. To test the ability of mono-2'-0-myristoyl c-di-GMP relative to stimulating an OVA-specific immune response, vaccines were prepared by combining 10 pg of OVA protein (OVA EndoFit, Invivogen) and Addavax (2 % of final squalene) with 0 (control) or 5 pg of mono-2'-O-myristoyl c-di-GMP derivative ("mono-2'-0-myristoyl CDG"), in a total volume of 100 pl . Groups of five female C57BL / 6 (H-2b) mice were immunized twice subcutaneously (SC) at the base of the tail with vaccine preparations and CD4 + and CD8 + T OVA-specific T cell responses in the spleens were determined by intracellular cytokine staining 7 days later. 1 x 106 splenocytes were stimulated or not with 1 pM MHC class I peptide (SIINFEKL OVA257-264; SL8) overnight and IFN-y production was measured by flow cytometer on a BD FACSVerse.
[227] As shown in Fig. 16, vaccines that contained mono-2'-O-myristoyl c-di-GMP derivative induced greater immune responses compared to control vaccines. These results demonstrate that a vaccine containing the mono-2'-O-myristoyl c-di-GMP derivative can stimulate highly potent adaptive immune responses in an animal model.
[228] A person skilled in the art readily appreciates that the present invention is well adapted to achieve the objectives and obtain the mentioned purposes and advantages, as well as those inherent in it. The examples provided in this document are representative of preferred modalities, are exemplary and are not intended to limit the scope of the invention.
[229] It should be understood that the invention is not limited in its application to the details of construction and arrangements of components set out in the following description or illustrated in the drawings. The invention is capable of other modalities in addition to those described and to be practiced or carried out in various ways. In addition, it should be understood that the phraseology and terminology used in this document, as well as in the abstract, is for description purposes and should not be considered as a limitation.
[230] As such, those skilled in the art will appreciate that the design on which this disclosure is based can readily be used as a basis for the design of other structures, methods and systems for carrying out various effects of the present invention. It is important, therefore, that the claims are considered to include such equivalent constructions, as they do not depart from the spirit and scope of the present invention.
[231] While the invention has been described and exemplified in sufficient detail for those skilled in the art to produce and use it, various alternatives, modifications and improvements must be apparent without departing from the spirit and scope of the invention. The examples provided in this document are representative of preferred modalities, are exemplary and are not intended to limit the scope of the invention. Modifications to it and other uses will occur for those skilled in the art. These modifications are encompassed within the spirit of the invention and are defined by the scope of the claims.
[232] It will be immediately apparent to an individual skilled in the art that different substitutions and modifications can be made to the invention disclosed in this document without deviating from the scope and spirit of the invention.
[233] All patents and publications mentioned in the specification are indicative of the levels of those versed in the technique to which the invention belongs. All patents and publications mentioned in this document are incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.
[234] The invention described in an illustrative manner in this document can be properly practiced in the absence of any element or elements, limitations or limitations that are not specifically disclosed in this document. Thus, for example, in each instance contained herein, any of the terms "comprising", "consisting essentially of" and "consisting of" can be replaced by any of the other two terms. The terms and expressions that have been used in this document are used as terms of description and not of limitation, and there is no intention in using such terms and expressions to exclude any equivalents of the features shown and described, or parts of them, but it is recognized that various modifications are possible in the scope of the claimed invention. Thus, it should be understood that, although the present invention has been specifically disclosed by preferential modalities and optional features, the modification and variation of the concepts disclosed in this document can be invoked by those skilled in the art, and that such modifications and variations are considered as being within the scope of the present invention, as defined by the added claims.
[235] Other modalities are established in the following claims.

权利要求:
Claims (13)
[0001]
1. Composition for use in a method of inducing an immune response to cancer in an individual, or inducing an immune response to a pathogen in an individual, characterized by the fact that it comprises one or more cyclic purine dinucleotides or their pharmaceutically acceptable salts which induce activation of TBK1 STING-dependent, in which the cyclic purine dinucleotides present in the composition are cyclic purine thiophosphate dinucleotides that are substantially pure Rp, Rp diastereoisomers, or pharmaceutically acceptable salts thereof, and in which the method comprises administration parenteral to the individual in need of the composition.
[0002]
Composition according to claim 1, characterized in that it comprises an inactivated tumor cell or a mixture of different tumor cells corresponding to the individual's type of cancer.
[0003]
3. Composition according to claim 2, characterized by the fact that the tumor cell is selected from the group consisting of a colorectal cancer cell, an aero-digestive squamous cancer cell, a lung cancer cell, a cancer cell brain cancer, a liver cancer cell, a stomach cancer cell, a sarcoma cell, a leukemia cell, a lymphoma cell, a multiple myeloma cell, an ovarian cancer cell, a cancer cell uterus, a breast cancer cell, a melanoma cell, a prostate cancer cell, a pancreatic carcinoma cell, and a renal carcinoma cell.
[0004]
Composition according to any one of claims 1 to 3, characterized in that the cyclic purine dinucleotide of thiophosphate is formulated with one or more lipids.
[0005]
5. Composition according to claim 4, characterized by the fact that one or more lipids comprise digitonin.
[0006]
Composition according to claim 4 or 5, characterized by the fact that one or more lipids form a liposome.
[0007]
Composition according to any one of claims 1 to 6, characterized in that the cyclic purine dinucleotide of thiophosphate is formulated with one or more adjuvants.
[0008]
Composition according to claim 7, characterized by the fact that one or more adjuvants comprise CpG and / or monophosphoryl lipid A.
[0009]
Composition according to any one of claims 1 to 8, characterized by the fact that the method additionally comprises the administration of one or more vaccines to the individual, wherein the vaccine (s) comprise one or more antigens selected for stimulate an immune response to a pathogen by expressing one or more of the antigens.
[0010]
Composition according to claim 9, characterized in that the vaccine (s) comprise inactivated or attenuated bacteria or viruses that include the antigens of interest, purified antigens, recombinantly designed live viral or bacterial delivery vectors for expressing and / or secreting antigens, antigen presenting cell vectors (APC) comprising cells that are loaded with the antigens or transfected with a composition comprising a nucleic acid encoding the antigens, liposomal antigen delivery vehicles comprising the antigens, or vectors of naked nucleic acid encoding the antigens.
[0011]
Composition according to any one of claims 1 to 10, characterized in that one or more cyclic purine dinucleotides of thiophosphate are formulated as a nanoparticle.
[0012]
Composition according to any one of claims 1 to 11, characterized in that the 2'-OH substituent of one or both ribose fractions of one or more cyclic purine dinucleotides is replaced with a substituent selected from the group consisting of fluorine, chlorine, bromine and iodine.
[0013]
Composition according to claim 12, characterized in that the 2'-OH substituent of one or both ribose fractions of one or more cyclic purine dinucleotides is replaced with fluorine.

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP6704012B2|2020-06-03|Compositions containing cyclic purine dinucleotides with defined stereochemistry and methods for their preparation and use

---

JP6453855B2|2019-01-16|Compositions and methods for activating &#34;interferon gene stimulator&#34; dependent signaling

---

US9770467B2|2017-09-26|Compositions and methods for cancer immunotherapy

---

JP6400082B2|2018-10-03|Compositions and methods for inhibiting &#34;stimulating factor of interferon gene&#34; dependent signaling

---

NZ707561B2|2021-03-02|Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use

同族专利:

---

公开号 | 公开日

---

EP3527579A1|2019-08-21|

---

JP6704012B2|2020-06-03|

---

JP2016503029A|2016-02-01|

---

DK2931738T3|2019-04-15|

---

CN105008381A|2015-10-28|

---

US20140205653A1|2014-07-24|

---

AU2013358892B2|2018-06-21|

---

SI2931738T1|2019-05-31|

---

EA201590396A1|2015-12-30|

---

US9695212B2|2017-07-04|

---

ES2718910T3|2019-07-05|

---

AU2018203682A1|2018-06-14|

---

MX361680B|2018-12-13|

---

HK1212707A1|2016-06-17|

---

AU2018203682B2|2020-07-02|

---

HUE043262T2|2019-08-28|

---

CA2886456A1|2014-06-19|

---

SG10201704611WA|2017-07-28|

---

US20170283454A1|2017-10-05|

---

JP6333843B2|2018-05-30|

---

BR112015013440A2|2017-07-11|

---

CN105008381B|2018-08-07|

---

US10414789B2|2019-09-17|

---

EP2931738B1|2019-02-06|

---

AU2013358892A1|2015-05-21|

---

PL2931738T3|2019-07-31|

---

EP2931738A1|2015-10-21|

---

EP2931738A4|2016-04-27|

---

SG11201502796RA|2015-05-28|

---

PT2931738T|2019-04-10|

---

JP2018135367A|2018-08-30|

---

CN108542913A|2018-09-18|

---

NZ707561A|2020-11-27|

---

WO2014093936A1|2014-06-19|

---

KR20150095668A|2015-08-21|

---

MX2015007447A|2015-12-09|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

GB9110808D0|1991-05-17|1991-07-10|Retroscreen Ltd|Aids vaccine and method for its production|

---

GB2257704B|1991-07-18|1995-03-01|Erba Carlo Spa|Cyclic oligonucleotides phosphorothioates|

---

US5637483A|1991-10-04|1997-06-10|Whitehead Institute For Biomedical Research|Irradiated tumor cell vaccine engineered to express GM-CSF|

---

US5904920A|1991-10-04|1999-05-18|Whitehead Institute For Biomedical Research|Regulation of systemic immune responses utilizing cytokines and antigens|

---

IT1262895B|1992-03-02|1996-07-22|Protein extracted from cytotoxic strains of Helicobacter pylori, gene expressing it, use of the protein as a vaccine or for diagnostic purposes.|

---

US5635160A|1995-06-07|1997-06-03|The University Of North Carolina At Chapel Hill|Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions|

---

US6033674A|1995-12-28|2000-03-07|Johns Hopkins University School Of Medicine|Method of treating cancer with a tumor cell line having modified cytokine expression|

---

US6277368B1|1996-07-25|2001-08-21|The Regents Of The University Of California|Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine|

---

EP1053301B1|1998-02-02|2004-04-21|The Johns Hopkins University School Of Medicine|A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use|

---

ID29546A|1999-02-15|2001-09-06|Nippon Shinyaku Co Ltd|POLINUKLEOTIDA WITH A SHORTED CHAIN AND THE METHOD OF MAKING IT|

---

US6558670B1|1999-04-19|2003-05-06|Smithkline Beechman Biologicals S.A.|Vaccine adjuvants|

---

EP1326638B9|2000-10-18|2008-02-20|GlaxoSmithKline Biologicals S.A.|Vaccines against cancers|

---

EP1320602A2|2000-09-21|2003-06-25|The Regents Of The University Of California|Spas-1 cancer antigen|

---

US7279883B2|2001-01-23|2007-10-09|Lydia L. Sohn|Particle analyzer and methods for use thereof|

---

TW200303759A|2001-11-27|2003-09-16|Schering Corp|Methods for treating cancer|

---

AR040996A1|2002-08-19|2005-04-27|Coley Pharm Group Inc|IMMUNE STIMULATING NUCLEIC ACIDS|

---

JP2007500697A|2003-07-28|2007-01-18|デイビッド・ケイ・アール・カラオリス|Method for reducing the toxicity of microbial pathogens and method for inhibiting microbial biofilm formation|

---

WO2005037233A2|2003-10-15|2005-04-28|Medimmune, Inc.|Listeria-based epha2 vaccines|

---

WO2005039535A1|2003-10-24|2005-05-06|Alza Corporation|Preparation of lipid particles|

---

US7592326B2|2004-03-15|2009-09-22|Karaolis David K R|Method for stimulating the immune, inflammatory or neuroprotective response|

---

JP4931798B2|2004-03-15|2012-05-16|ケイ．アール． カラオリス，デイヴィッド|Methods for immune, inflammatory or neuroprotective responses|

---

CA2607579A1|2005-05-06|2006-11-23|The Regents Of The University Of California|Microfluidic system for identifying or sizing individual particles passing through a channel|

---

US20070059683A1|2005-09-15|2007-03-15|Tom Barber|Veterinary diagnostic system|

---

EP1782826A1|2005-11-08|2007-05-09|GBF Gesellschaft für Biotechnologische Forschung mbH|PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions|

---

CA2631931C|2005-12-01|2014-04-29|Pronai Therapeutics, Inc.|Cancer therapies and pharmaceutical compositions used therein|

---

CA2659301A1|2006-07-28|2008-02-07|Applera Corporation|Dinucleotide mrna cap analogs|

---

AU2007292302A1|2006-09-05|2008-03-13|Bipar Sciences, Inc.|Methods for designing PARP inhibitors and uses thereof|

---

TWI444384B|2008-02-20|2014-07-11|Gilead Sciences Inc|Nucleotide analogues and their use in the treatment of malignancies|

---

WO2010017248A2|2008-08-04|2010-02-11|University Of Miami|Sting , a regulator of innate immune responses|

---

EP2844756A4|2012-04-30|2016-02-24|Glen N Barber|Modulating immune responses|

---

US8840881B2|2008-08-28|2014-09-23|Aduro Gvax Inc.|Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer|

---

PE20110998A1|2008-12-09|2012-02-10|Coley Pharm Group Inc|IMMUNOSTIMULATORY OLIGONUCLEOTIDES|

---

WO2010104883A1|2009-03-09|2010-09-16|Molecular Express, Inc.|Methods and compositions for liposomal formulation of antigens and uses thereof|

---

US8414630B2|2009-03-10|2013-04-09|Marc Evan Richelsoph|Active bone screw|

---

MX360448B|2009-06-05|2018-11-01|Infectious Disease Res Inst|Synthetic glucopyranosyl lipid adjuvants.|

---

WO2011003025A1|2009-07-01|2011-01-06|Rutgers, The State University Of New Jersey|Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof|

---

US8771933B2|2009-10-06|2014-07-08|Massachusetts Institute Of Technology|Continuous-flow deformability-based cell separation|

---

MX339050B|2009-12-18|2016-05-09|Novartis Ag|Organic compositions to treat hsf1-related diseases.|

---

EP2361911A1|2010-02-18|2011-08-31|GenKyoTex SA|Pyrazolo piperidine derivatives as NADPH oxidase inhibitors|

---

US20110293558A1|2010-03-22|2011-12-01|Massachusetts Institute Of Technology|Material properties of t cells and related methods and compositions|

---

CN102199183B|2010-03-26|2013-12-18|北京大学|C-di-GMP, analogues thereof and preparation method thereof|

---

BR112012027745A2|2010-04-27|2017-01-10|Univ Johns Hopkins|method and immunogenic composition for treatment of neoplasia|

---

US8450293B2|2010-08-10|2013-05-28|Rutgers, The State University Of New Jersey|Synthesis and characterization of C8 analogs of c-di-GMP|

---

RS57630B1|2010-11-17|2018-11-30|Aduro Biotech Inc|Methods and compositions for inducing an immune response to egfrviii|

---

US9061048B2|2010-12-15|2015-06-23|The Regents Of The University Of California|Cyclic di-AMP induction of type I interferon|

---

AU2011349278C1|2010-12-22|2017-01-19|Alios Biopharma, Inc.|Cyclic nucleotide analogs|

---

JP5990256B2|2011-04-15|2016-09-07|ザ ユニバーシティ オブ ブリティッシュ コロンビアＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｂｒｉｔｉｓｈ Ｃｏｌｕｍｂｉａ|Particle separation method and apparatus|

---

WO2013086331A1|2011-12-07|2013-06-13|President And Fellows Of Harvard College|High efficiency di-nucleotide cyclase|

---

CA2876150A1|2012-06-08|2013-12-12|The Johns Hopkins University|Compostions and methods for cancer immunotherapy|

---

CN112587658A|2012-07-18|2021-04-02|博笛生物科技有限公司|Targeted immunotherapy for cancer|

---

US9090646B2|2012-12-05|2015-07-28|Rutgers, The State University Of New Jersey|Biotinylated compounds|

---

KR20150095668A|2012-12-13|2015-08-21|아두로 바이오테크, 인코포레이티드|Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use|

---

PT2934598T|2012-12-19|2018-07-24|Univ Texas|Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway|

---

SG10201708821RA|2013-04-29|2017-12-28|Memorial Sloan Kettering Cancer Center|Compositions and methods for altering second messenger signaling|

---

JP2016518140A|2013-05-03|2016-06-23|ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア|Method for inducing cyclic dinucleotide of type I interferon|

---

US9549944B2|2013-05-18|2017-01-24|Aduro Biotech, Inc.|Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling|

---

JP6400082B2|2013-05-18|2018-10-03|アデュロ バイオテック，インコーポレイテッド|Compositions and methods for inhibiting "stimulating factor of interferon gene" dependent signaling|

---

SG11201508273RA|2013-05-18|2015-12-30|Aduro Biotech Inc|Compositions and methods for activating "stimulator of interferon gene"-dependent signalling|

---

WO2015017652A1|2013-07-31|2015-02-05|Memorial Sloan-Kettering Cancer Center|Sting crystals and modulators|

---

EP3060056A4|2013-10-21|2017-10-18|Drexel University|Use of sting agonists to treat chronic hepatitis b virus infection|

---

EP3071209A4|2013-11-19|2017-08-16|The University of Chicago|Use of sting agonist as cancer treatment|

---

US10092644B2|2013-11-22|2018-10-09|Brock University|Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants|

---

WO2015085565A1|2013-12-13|2015-06-18|Qualcomm Incorporated|Methods and apparatus for cell selection in a wireless communication system|

---

US10421971B2|2014-01-15|2019-09-24|The University Of Chicago|Anti-tumor therapy|

---

CA2950033A1|2014-06-04|2015-12-10|Glaxosmithkline Intellectual Property Development Limited|Cyclic di-nucleotides as modulators of sting|

---

WO2016096174A1|2014-12-16|2016-06-23|Invivogen|Fluorinated cyclic dinucleotides for cytokine induction|

---

GB201501462D0|2015-01-29|2015-03-18|Glaxosmithkline Ip Dev Ltd|Novel compounds|

---

WO2016145102A1|2015-03-10|2016-09-15|Aduro Biotech, Inc.|Compositions and methods for activating "stimulator of interferon gene" -dependent signalling|

---

JOP20200224A1|2015-08-13|2017-06-16|Merck Sharp & Dohme|Cyclic di-nucleotide compounds as sting agonists|

---

EP3322713B1|2015-12-03|2021-01-20|GlaxoSmithKline Intellectual Property Development Limited|Cyclic purine dinucleotides as modulators of sting|US11202759B2|2010-10-06|2021-12-21|President And Fellows Of Harvard College|Injectable, pore-forming hydrogels for materials-based cell therapies|

---

CA2876150A1|2012-06-08|2013-12-12|The Johns Hopkins University|Compostions and methods for cancer immunotherapy|

---

KR20150095668A|2012-12-13|2015-08-21|아두로 바이오테크, 인코포레이티드|Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use|

---

PT2934598T|2012-12-19|2018-07-24|Univ Texas|Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway|

---

SG10201708821RA|2013-04-29|2017-12-28|Memorial Sloan Kettering Cancer Center|Compositions and methods for altering second messenger signaling|

---

JP2016518140A|2013-05-03|2016-06-23|ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア|Method for inducing cyclic dinucleotide of type I interferon|

---

SG11201508273RA|2013-05-18|2015-12-30|Aduro Biotech Inc|Compositions and methods for activating "stimulator of interferon gene"-dependent signalling|

---

US9549944B2|2013-05-18|2017-01-24|Aduro Biotech, Inc.|Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling|

---

JP6400082B2|2013-05-18|2018-10-03|アデュロ バイオテック，インコーポレイテッド|Compositions and methods for inhibiting "stimulating factor of interferon gene" dependent signaling|

---

WO2015017652A1|2013-07-31|2015-02-05|Memorial Sloan-Kettering Cancer Center|Sting crystals and modulators|

---

EP3071209A4|2013-11-19|2017-08-16|The University of Chicago|Use of sting agonist as cancer treatment|

---

CN103908468B|2014-04-21|2017-02-08|上海捌加壹医药科技有限公司|Application of cyclic dinucleotide cGAMP in preparing anti-tumor medicaments|

---

US10682400B2|2014-04-30|2020-06-16|President And Fellows Of Harvard College|Combination vaccine devices and methods of killing cancer cells|

---

CA2950033A1|2014-06-04|2015-12-10|Glaxosmithkline Intellectual Property Development Limited|Cyclic di-nucleotides as modulators of sting|

---

JP6762030B2|2014-11-20|2020-09-30|国立研究開発法人医薬基盤・健康・栄養研究所|New Th1-inducible adjuvants and their uses by combining different nucleic acid adjuvants|

---

WO2016096174A1|2014-12-16|2016-06-23|Invivogen|Fluorinated cyclic dinucleotides for cytokine induction|

---

GB201501462D0|2015-01-29|2015-03-18|Glaxosmithkline Ip Dev Ltd|Novel compounds|

---

US10130663B2|2015-02-11|2018-11-20|The John Hopkins University|Bacteria over-expressing c-di-AMP and therapeutic methods|

---

WO2016145102A1|2015-03-10|2016-09-15|Aduro Biotech, Inc.|Compositions and methods for activating "stimulator of interferon gene" -dependent signalling|

---

EP3302527B1|2015-06-03|2020-01-08|The Medical College of Wisconsin, Inc.|An engineered ccl20 locked dimer polypeptide|

---

JOP20200224A1|2015-08-13|2017-06-16|Merck Sharp & Dohme|Cyclic di-nucleotide compounds as sting agonists|

---

MA48579A|2015-09-01|2020-03-18|Agenus Inc|ANTI-PD1 ANTIBODIES AND METHODS OF USING THEM|

---

CN105367617A|2015-09-25|2016-03-02|武汉品生科技有限公司|Derivative based on c-di-AMP, tat polypeptide and application of derivative in inhibitor in type I interferon micromolecules|

---

AU2016343993A1|2015-10-28|2018-05-10|Aduro Biotech, Inc.|Compositions and methods for activating "stimulator of interferon gene"-dependent signalling|

---

CN106539813B|2015-11-30|2019-12-03|杭州星鳌生物科技有限公司|Application of interferon-stimulated geneactivator in anti-inflammatory|

---

EP3322713B1|2015-12-03|2021-01-20|GlaxoSmithKline Intellectual Property Development Limited|Cyclic purine dinucleotides as modulators of sting|

---

CN106539814A|2015-12-09|2017-03-29|聊城市奥润生物医药科技有限公司|Interferon gene stimulatory protein（STING）Application of the agonist in the diseases such as resisting rheumatoid arthritis|

---

CN106540260A|2015-12-09|2017-03-29|聊城市奥润生物医药科技有限公司|Interferon gene stimulatory protein（STING）Application of the agonist in anti-alzheimer's disease|

---

CN106554416B|2015-12-09|2019-03-15|聊城市奥润生物医药科技有限公司|A kind of application of anti-PD-L1 Humanized monoclonal antibodies joint interferon gene stimulates the proteinagonist in antitumor|

---

US20170199961A1|2015-12-16|2017-07-13|Gritstone Oncology, Inc.|Neoantigen Identification, Manufacture, and Use|

---

US20180369268A1|2015-12-16|2018-12-27|Aduro Biotech, Inc.|Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production|

---

SG11201805888SA|2016-01-11|2018-08-30|Innate Tumor Immunity Inc|Cyclic dinucleotides for treating conditions associated with sting activity such as cancer|

---

CA3016457A1|2016-03-02|2017-09-08|The Board Of Regents Of The University Of Texas System|Sting activating nanovaccine for immunotherapy|

---

JP6980198B2|2016-03-18|2021-12-15|イミューン センサー リミテッド ライアビリティ カンパニー|Cyclic dinucleotide compound and usage|

---

CN106539757A|2016-03-20|2017-03-29|聊城市奥润生物医药科技有限公司|Application of the ring dinucleotide cGAMP- liposomees in antitumor|

---

PE20181919A1|2016-04-07|2018-12-11|Glaxosmithkline Ip Dev Ltd|USEFUL HETEROCYCLIC AMIDES AS PROTEIN MODULATORS|

---

JP2019510802A|2016-04-07|2019-04-18|グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ|Heterocyclic amides useful as protein modulators|

---

EP3448393A1|2016-04-25|2019-03-06|Invivogen|Novel complexes of immunostimulatory compounds, and uses thereof|

---

US10696985B1|2016-06-06|2020-06-30|Vanderbilt University|Reversibly crosslinked endosomolytic polymer vesicles for cytosolic drug delivery|

---

US11098077B2|2016-07-05|2021-08-24|Chinook Therapeutics, Inc.|Locked nucleic acid cyclic dinucleotide compounds and uses thereof|

---

MX2019000216A|2016-07-06|2019-11-12|Sperovie Biosciences Inc|Compounds, compositions, and methods for the treatment of disease.|

---

WO2018013924A1|2016-07-15|2018-01-18|Massachusetts Institute Of Technology|Synthetic nanoparticles for delivery of immunomodulatory compounds|

---

DE102016113714A1|2016-07-26|2018-02-01|Rosa Karl|Transfection procedure with non-viral gene delivery systems|

---

NL2017267B1|2016-07-29|2018-02-01|Aduro Biotech Holdings Europe B V|Anti-pd-1 antibodies|

---

NL2017270B1|2016-08-02|2018-02-09|Aduro Biotech Holdings Europe B V|New anti-hCTLA-4 antibodies|

---

DK3506884T3|2016-08-30|2021-07-26|Dana Farber Cancer Inst Inc|COMPOSITIONS FOR THE ADMINISTRATION OF MEDICINES AND USES OF THESE|

---

WO2018053508A1|2016-09-19|2018-03-22|The University Of North Carolina At Chapel Hill|Methods and compositions for inducing an immune response|

---

US10537590B2|2016-09-30|2020-01-21|Boehringer Ingelheim International Gmbh|Cyclic dinucleotide compounds|

---

PE20190705A1|2016-10-04|2019-05-17|Merck Sharp & Dohme|BENZO COMPOUNDS [b] THIOPHEN AS STING AGONISTS|

---

WO2018065360A1|2016-10-07|2018-04-12|Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh|Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes -dependent signaling pathways|

---

US10266558B2|2016-10-07|2019-04-23|Alexandre Vasilievich Ivachtchenko|Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof|

---

JOP20170192A1|2016-12-01|2019-01-30|Takeda Pharmaceuticals Co|Cyclic dinucleotide|

---

WO2018119117A1|2016-12-22|2018-06-28|The Regents Of The University Of California|Methods of producing cyclic dinucleotides|

---

JP2018131427A|2017-02-17|2018-08-23|国立研究開発法人理化学研究所|Technology for controlling immune cells|

---

US20200055883A1|2017-02-17|2020-02-20|Eisai R&D Management Co., Ltd.|Cyclic di-nucleotides derivative for the treatment of cancer|

---

WO2018156625A1|2017-02-21|2018-08-30|Board Of Regents,The University Of Texas System|Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling|

---

CN106928298B|2017-03-13|2021-10-22|杭州星鳌生物科技有限公司|Structural composition of cyclic dinucleotide cGAMP derivative, preparation method and application of cyclic dinucleotide cGAMP derivative in tumor resistance|

---

AU2018239468A1|2017-03-22|2019-09-12|Boehringer Ingelheim International Gmbh|Modified cyclic dinucleotide compounds|

---

WO2018190719A2|2017-04-13|2018-10-18|Aduro Biotech Holdings, Europe B.V.|Anti-sirp alpha antibodies|

---

EP3610022A1|2017-04-14|2020-02-19|Tollnine, Inc.|Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use|

---

AR113224A1|2017-04-28|2020-02-19|Novartis Ag|ANTIBODY CONJUGATES INCLUDING A STING AGONIST|

---

UY37695A|2017-04-28|2018-11-30|Novartis Ag|BIS 2’-5’-RR- CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME|

---

EP3841112A1|2018-08-24|2021-06-30|Codiak BioSciences, Inc.|Extracellular vesicles targeting dendritic cells and uses thereof|

---

KR20200055037A|2017-09-19|2020-05-20|메사추세츠 인스티튜트 오브 테크놀로지|Compositions and uses for chimeric antigen receptor T cell therapy|

---

EP3692034A1|2017-10-05|2020-08-12|GlaxoSmithKline Intellectual Property Development Limited|Modulators of stimulator of interferon genes |

---

EP3692033A1|2017-10-05|2020-08-12|GlaxoSmithKline Intellectual Property Development Limited|Modulators of stimulator of interferon genesuseful in treating hiv|

---

WO2019075112A1|2017-10-10|2019-04-18|Gritstone Oncology, Inc.|Neoantigen identification using hotspots|

---

EP3710007A4|2017-11-14|2021-12-15|Children's Medical Center Corporation|Use of imidazopyrimidine for modulating human immune response|

---

US10966999B2|2017-12-20|2021-04-06|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein|

---

US11203610B2|2017-12-20|2021-12-21|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein|

---

WO2019161171A1|2018-02-16|2019-08-22|Sperovie Biosciences, Inc.|Nanoparticle formulations of sting agonists|

---

BR112020019089A2|2018-03-23|2020-12-29|Codiak Biosciences, Inc.|EXTRACELLULAR VESICLES UNDERSTANDING STING AGONIST|

---

WO2019185476A1|2018-03-27|2019-10-03|Boehringer Ingelheim International Gmbh|Modified cyclic dinucleotide compounds|

---

WO2019185477A1|2018-03-27|2019-10-03|Boehringer Ingelheim International Gmbh|Cyclic dinucleotide compounds containing 2-aza-hypoxanthine or 6h-pytazolo[1,5-d][1,2,4]triazin-7-one as sting agonists|

---

EP3774764A1|2018-04-03|2021-02-17|Merck Sharp&Dohme Corp.|Benzothiophenes and related compounds as sting agonists|

---

TW202005654A|2018-04-06|2020-02-01|捷克科學院有機化學與生物化學研究所|2'2'-cyclic dinucleotides|

---

TW202005655A|2018-04-06|2020-02-01|捷克科學院有機化學與生物化學研究所|2'3'-cyclic dinucleotides|

---

TW202010503A|2018-04-06|2020-03-16|捷克科學院有機化學與生物化學研究所|3’3’－cyclic dinucleotides|

---

TW202014193A|2018-05-03|2020-04-16|捷克科學院有機化學與生物化學研究所|2’3’-cyclic dinucleotides comprising carbocyclic nucleotide|

---

GB201807924D0|2018-05-16|2018-06-27|Ctxt Pty Ltd|Compounds|

---

CA3101368A1|2018-05-25|2019-11-28|Incyte Corporation|Tricyclic heterocyclic compounds as sting activators|

---

CN112512531A|2018-06-01|2021-03-16|卫材R&D管理有限公司|Methods for treatment of bladder cancer|

---

US10875872B2|2018-07-31|2020-12-29|Incyte Corporation|Heteroaryl amide compounds as sting activators|

---

US11008344B2|2018-07-31|2021-05-18|Incyte Corporation|Tricyclic heteroaryl compounds as STING activators|

---

WO2020027309A1|2018-08-03|2020-02-06|国立大学法人東京大学|Intranasal vaccine that induces cellular immunity|

---

EP3848054A1|2018-09-06|2021-07-14|Daiichi Sankyo Company, Limited|Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof|

---

CN110938104A|2018-09-21|2020-03-31|上海迪诺医药科技有限公司|Cyclic dinucleotide analogs, pharmaceutical compositions and uses thereof|

---

US11110106B2|2018-10-29|2021-09-07|Venenum Biodesign, LLC|Sting agonists for treating bladder cancer and solid tumors|

---

AU2019371206A1|2018-10-29|2021-05-27|Venenum Biodesign, LLC|Novel sting agonists|

---

WO2020092633A1|2018-10-30|2020-05-07|Vanderbilt University|Graft copolymers, methods of forming graft copolymers, and methods of use thereof|

---

EP3873938A1|2018-10-31|2021-09-08|Novartis AG|Dc-sign antibody conjugates comprising sting agonists|

---

WO2020178768A1|2019-03-07|2020-09-10|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator|

---

WO2020178769A1|2019-03-07|2020-09-10|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|2'3'-cyclic dinucleotides and prodrugs thereof|

---

WO2020178770A1|2019-03-07|2020-09-10|Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.|3'3'-cyclic dinucleotides and prodrugs thereof|

---

SG11202109702QA|2019-03-21|2021-10-28|Codiak Biosciences Inc|Extracellular vesicles for vaccine delivery|

---

EP3941528A1|2019-03-21|2022-01-26|Codiak BioSciences, Inc.|Extracellular vesicle conjugates and uses thereof|

---

WO2021189047A2|2020-03-20|2021-09-23|Codiak Biosciences, Inc.|Extracellular vesicles for therapy|

---

WO2020191369A1|2019-03-21|2020-09-24|Codiak Biosciences, Inc.|Process for preparing extracellular vesicles|

---

TW202104214A|2019-04-05|2021-02-01|英商葛蘭素史密斯克藍智慧財產發展有限公司|Chemical compounds|

---

WO2020227159A2|2019-05-03|2020-11-12|Flagship Pioneering Innovations V, Inc.|Methods of modulating immune activity|

---

EP3965891A1|2019-05-10|2022-03-16|Takeda Pharmaceutical Company Limited|Antibody drug conjugates|

---

WO2021003445A1|2019-07-03|2021-01-07|Codiak Biosciences, Inc.|Extracellular vesicles targeting t cells and uses thereof|

---

GB201910304D0|2019-07-18|2019-09-04|Ctxt Pty Ltd|Compounds|

---

GB201910305D0|2019-07-18|2019-09-04|Ctxt Pty Ltd|Compounds|

---

WO2021030251A1|2019-08-12|2021-02-18|Purinomia Biotech, Inc.|Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells|

---

WO2021041532A1|2019-08-26|2021-03-04|Dana-Farber Cancer Institute, Inc.|Use of heparin to promote type 1 interferon signaling|

---

WO2021062060A1|2019-09-25|2021-04-01|Codiak Biosciences, Inc.|Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour|

---

WO2021062317A1|2019-09-25|2021-04-01|Codiak Biosciences, Inc.|Extracellular vesicle compositions|

---

WO2021062290A1|2019-09-25|2021-04-01|Codiak Biosciences, Inc.|Methods of producing extracellular vesicles|

---

WO2021062058A1|2019-09-25|2021-04-01|Codiak Biosciences, Inc.|Sting agonist comprising exosomes for treating neuroimmunological disorders|

---

WO2021074695A1|2019-10-16|2021-04-22|Avacta Life Sciences Limited|PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.|

---

WO2021113679A1|2019-12-06|2021-06-10|Mersana Therapeutics, Inc.|Dimeric compounds as sting agonists|

---

US11179473B2|2020-02-21|2021-11-23|Silverback Therapeutics, Inc.|Nectin-4 antibody conjugates and uses thereof|

---

WO2021184017A1|2020-03-13|2021-09-16|Codiak Biosciences, Inc.|Extracellular vesicles for treating neurological disorders|

---

WO2021216572A1|2020-04-20|2021-10-28|Massachusetts Institute Of Technology|Lipid compositions for delivery of sting agonist compounds and uses thereof|

---

WO2021221783A1|2020-05-01|2021-11-04|Massachusetts Institute Of Technology|Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof|

---

US20210338833A1|2020-05-01|2021-11-04|Massachusetts Institute Of Technology|Chimeric antigen receptor-targeting ligands and uses thereof|

---

US20210354984A1|2020-05-13|2021-11-18|Massachusetts Institute Of Technology|Compositions of polymeric microdevices and methods of use thereof in cancer immunotherapy|

---

WO2021237100A1|2020-05-21|2021-11-25|Codiak Biosciences, Inc.|Methods of targeting extracellular vesicles to lung|

法律状态:
2018-01-16| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2018-03-06| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2018-03-13| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2018-03-20| B06I| Publication of requirement cancelled [chapter 6.9 patent gazette]|Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |

---

2019-05-21| B07E| Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |

---

2019-10-29| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2020-06-09| B06A| Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]|

---

2020-08-11| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2020-12-08| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/12/2013, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US201261737006P| true| 2012-12-13|2012-12-13|

---

US61/737,006|2012-12-13|

---

US201361790514P| true| 2013-03-15|2013-03-15|

---

US61/790,514|2013-03-15|

---

PCT/US2013/075189|WO2014093936A1|2012-12-13|2013-12-13|Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use|

---